



MGM INSTITUTE OF HEALTH SCIENCES

(Deemed University u/s 3 of UGC Act, 1956)

Grade 'A++' Accredited by NAAC

Sector-01, Kamothe, Navi Mumbai - 410 209

Tel 022-27432471, 022-27432994, Fax 022 - 27431094

E-mail : registrar@mgmuhs.com ; Website : www.mgmuhs.com

AQAR 2023-24

Sr. No.	Major Achievements	Page no
1	MGMIHS accredited as Grade 'A++' with CGPA grade 3.55 by NAAC	3-5
2	MGMIHS scored Diamond rating in QS I-Gauge	6-10
3	MGMIHS got 15th rank in India Today MDRA Best University Ranking 2024	11-12
4	12B Status	12-13
5	Category I Institute	14-15
6	Renewal of Blood Centre License No. KD – 36	16-18
7	NIRF 2023 (University Rank Band 151-200)	19-20
8	3 Star Certificate of Institution's Innovation Council (IIC) for the Academic Year 2022-23	21-22
9	SIRO Renewal	23-25
10	NABH Accredited Hospitals – Kamothe	26-27
11	NABH Accredited Hospitals – Aurangabad	28-29
12	NABH Accredited Hospitals – Vashi	30-31
13	NABL Accredited laboratories - Kamothe	32-33
14	NABL Accredited laboratories – Aurangabad	34-35
15	NABL Accredited Hospitals – Vashi	36-37
16	Neighborhood Youth Parliament and Y20 Consultation	38-39
17	Eat Right Campus Certificate	40-41
18	Center of Excellence for Laparoscopy surgery by Storz, Karl Storz endoscope	42-43
19	American Heart Association	44-46
20	Institutional Animal Ethics Committee (IAEC) -Navi Mumbai	47-49



MGM INSTITUTE OF HEALTH SCIENCES

(Deemed University u/s 3 of UGC Act, 1956)

Grade 'A⁺⁺' Accredited by NAAC

Sector-01, Kamothe, Navi Mumbai - 410 209

Tel 022-27432471, 022-27432994, Fax 022 - 27431094

E-mail : registrar@mgmuhs.com ; Website : www.mgmuhs.com

AQAR 2023-24

Sr. No.	Major Achievements	Page no
21	Institutional Animal Ethics Committee (IAEC) -Aurangabad	50-54
22	Ethics Committee Registration, MGM Institute of Health Sciences, Navi Mumbai	55-63
23	Ethics Committee Registration, MGM Medical College and Hospital, Aurangabad	64-69
24	Zonal Transplantation Coordination Center, Aurangabad	70-82
25	Adverse Drug Reactions Monitoring Centre (AMC)- Navi Mumbai	83-85
26	Adverse Drug Reactions Monitoring Centre (AMC)- Aurangabad	86-87

NAAC Certification



राष्ट्रीय मूल्यांकन एवं प्रत्यायन परिषद
विश्वविद्यालय अनुदान आयोग का स्वायत्त संस्थान
NATIONAL ASSESSMENT AND ACCREDITATION COUNCIL
An Autonomous Institution of the University Grants Commission

Certificate of Accreditation

*The Executive Committee of the
National Assessment and Accreditation Council
is pleased to declare*

*MSM Institute of Health Sciences, Navi Mumbai
(Deemed to be University u/s 3 of the UGC Act, 1956)
Sector-1, Kamothe, Navi Mumbai, Maharashtra as
Accredited*

*with CGPA of 3.55 on four point scale
at A⁺⁺ grade
valid up to July 18, 2027*

Date : July 19, 2022



S. C. Sharma
Director



राष्ट्रीय मूल्यांकन एवं प्रत्यायन परिषद
विश्वविद्यालय अनुदान आयोग का स्वायत्त संस्थान
NATIONAL ASSESSMENT AND ACCREDITATION COUNCIL
An Autonomous Institution of the University Grants Commission

Quality Profile

Name of the Institution : MGM Institute of Health Sciences, Navi Mumbai


Place : Sector-1, Kamothe, Navi Mumbai, Maharashtra

Criteria	Weightage (W_i)	Criterion-wise Weighted Grade Point ($Cr\ WGP_i$)	Criterion-wise Grade Point Averages ($Cr\ WGP_i / W_i$)
I. Curricular Aspects	150	585	3.90
II. Teaching-Learning and Evaluation	200	726	3.63
III. Research, Innovations and Extension	250	711	2.84
IV. Infrastructure and Learning Resources	100	351	3.51
V. Student Support and Progression	100	388	3.88
VI. Governance, Leadership & Management	100	392	3.92
VII. Institutional Values and Best Practices	100	400	4.00
Total	$\sum_{i=1}^7 W_i = 1000$	$\sum_{i=1}^7 (Cr\ WGP_i) = 3553$	

$$\text{Institutional CGPA} = \frac{\sum_{i=1}^7 (Cr\ WGP_i)}{\sum_{i=1}^7 W_i} = \frac{3553}{1000} = \boxed{3.55}$$

Grade = **A⁺⁺**

Date : July 19, 2022



(Signature)
Director

- This certification is valid for a period of Five years with effect from July 19, 2022
- An institutional CGPA on four point scale in the range of 3.51 - 4.00 denotes A⁺⁺ grade, 3.26 - 3.50 denotes A⁺ grade, 3.01 - 3.25 denotes A grade, 2.76 - 3.00 denotes B⁺⁺ grade, 2.51 - 2.75 denotes B⁺ grade, 2.01 - 2.50 denotes B grade, 1.51 - 2.00 denotes C grade
- Scores rounded off to the nearest integer

**MGMIHS scored Diamond
rating in QS I-Gauge**



I-GAUGE



**Teaching and
Learning**



Faculty Quality



Employability



**Diversity and
Accessibility**



Facilities



Social Responsibility



**Governance
and Structure**



Arts and Culture



Entrepreneurship



Research



Innovation



Internationalisation



Academic Development

INSTITUTIONAL SCORECARD

**MGM INSTITUTE OF HEALTH SCIENCES (MGMIHS)
MAHARASHTRA**

2024-2026



I-GAUGE

INSTITUTIONAL SCORECARD

DIAMOND



I-GAUGE


INDIAN UNIVERSITY RATINGS



2024-2026

License Valid Till: 27.08.2026

Pathway to Excellence



**MGMIHS got 15th rank
in India Today MDRA
Best University Ranking
2024**



INDIA
TODAY

Login

Subscribe Magazine



College Rankings

News

Best Emerging Colleges

Jobs in Demand

Exams

Best Universities

Methodology

Search

0

☐ Jamnagar

☐ Jodhpur

Ownership

☐ Govt.

☐ Pvt.

NITTE (Deemed to be University)

Cutoff Fees Add To Compare

Overall Rank		City	REG	ARE	ILE	PLD	CPP	O.S.	P.S.	Total Score
2024	2023		(225)	(225)	(200)	(150)	(200)	(1000)	(1000)	(2000)
13	14	Vijayapura	164.4	114	137.5	76	147.1	639	649.3	1288.3

KLE Academy of Higher Education & Research

Cutoff Fees Add To Compare

14	16	Belagavi	149.8	150.7	170.6	82	122	675.1	501.4	1176.5
----	----	----------	-------	-------	-------	----	-----	-------	-------	--------

MGM Institute of Health Sciences

Cutoff Fees Add To Compare

15	NP	Navi Mumbai	153.7	113.9	140.5	86.4	151	645.5	411.6	1057.1
----	----	-------------	-------	-------	-------	------	-----	-------	-------	--------

DY Patil Education Society

Cutoff Fees Add To Compare

16	17	Kolhapur	147	118.1	145	70.1	105.6	585.8	463.8	1049.6
----	----	----------	-----	-------	-----	------	-------	-------	-------	--------

Sri Guru Ram Das University of Health Sciences

Cutoff Fees Add To Compare

17	18	Amritsar	155.4	108.2	159.1	64.3	91.2	578.2	327.5	905.7
----	----	----------	-------	-------	-------	------	------	-------	-------	-------

Sri Balaji Vidyapeeth

Cutoff Fees Add To Compare

18	19	Puducherry	130.9	123.5	146	103.5	141.7	645.6	217.4	863
----	----	------------	-------	-------	-----	-------	-------	-------	-------	-----

Chettinad Academy of Research and Education

Cutoff Fees Add To Compare

19	NP	Kelambakkam	138.3	119.1	141.1	91.4	104.8	594.7	194.2	788.9
----	----	-------------	-------	-------	-------	------	-------	-------	-------	-------

Showing 1 to 19 of total 19 entries

12B Status

Dr. N.Gopukumar
Joint Secretary
Ph. 011-23604219
www.ugc.ac.in
email: gopukumar.ugc@nic.in



विश्वविद्यालय अनुदान आयोग
बहादुरशाह जफर मार्ग
नई दिल्ली-110 002
UNIVERSITY GRANTS COMMISSION
BAHADURSHAH ZAFAR MARG
NEW DELHI-110 002

By Email

No.F.1-1/2023 (CPP-I/DU)

October, 2023

06 OCT 2023

**The Registrar,
MGM Institute of Health Sciences
(Deemed to be University),
MGM Campus, Sector – 1,
Kamothe, Navi Mumbai– 410209,
Maharashtra.**

Subject: Proposals for inclusion in the list of Deemed to be Universities under Section 12 B of the UGC Act, 1956.

Sir,

This has reference to your application submitted for 12B status. The Commission in its 572nd meeting held on 20.09.2023 considered the application and decided to grant 12B status to MGM Institute of Health Sciences (Deemed to be University), MGM Campus, Sector – 1, Kamothe, Navi Mumbai– 410209, Maharashtra. The status is subject to the condition that the financial assistance under all UGC schemes shall be limited to those relating to teachers and students only.

Accordingly, the MGM Institute of Health Sciences (Deemed to be University) is included under section 12B of the UGC Act 1956 to be eligible for central assistance.

Yours faithfully,

(N.Gopukumar)

Category I Institute



सचिव

Secretary



विश्वविद्यालय अनुदान आयोग
University Grants Commission

(शिक्षा मंत्रालय, भारत सरकार)
(Ministry of Education, Govt. of India)

बहादुरशाह जफर मार्ग, नई दिल्ली-110002
Bahadur Shah Zafar Marg, New Delhi-110002

Ph.: 011-23236288/23239337

Fax : 011-2323 8858

E-mail : secy.ugc@nic.in

No.F.1-1/2018 (CPP-I/DU)

December, 2022

The Vice Chancellor,
MGM Institute of Health Sciences,
(Deemed to be University),
Sector-1, Kamothe,
Navi Mumbai,
Maharashtra

05 DEC 2022

Subject: Categorization of the Deemed to be University under UGC [Categorization of Universities (only) for Grant of Graded Autonomy] Regulations, 2018.

Sir,

As you are aware, UGC is mandated to determine, promote and maintain the standards of higher education in the country. UGC is constantly striving to create an enabling environment whereby higher education institutions in the country can become institution of global excellence. UGC is also aware that global excellence can be achieved only by extending autonomy to better performing institutions as autonomy is pivotal to promoting and institutionalization excellence in higher education.


In order to grant autonomy to the better performing institutions, UGC has notified UGC [Categorization of Universities (only) for Graded Autonomy] Regulations, 2018 on 12th February, 2018 in the Gazette of India.

The proposal received from MGM Institute of Health Sciences, (Deemed to be University), Navi Mumbai, Maharashtra under the above regulations has been examined, processed and considered by the UGC. **The UGC has decided to grade MGM Institute of Health Sciences, (Deemed to be University), Navi Mumbai, Maharashtra as Category-I Deemed to be University as per the provisions of the above UGC Regulations.** The Deemed to be University shall now be eligible for all the benefits as stipulated under Clause 4 (Dimensions of Autonomy for Category-I Universities) of the abovementioned UGC Regulations, 2018.

The Deemed to be University shall inform the UGC about the benefit being implemented from new academic session. In light of this, the Deemed to be University should acknowledge in writing that it shall strictly comply with all the regulations as mentioned in the provisions (clause-4) of the UGC [Categorization of Universities (only) for Graded Autonomy] Regulations, 2018.

It is further informed that the Deemed to be University shall intimate the Commission about its changed status as per Clause 6 of the said Regulations.

Yours faithfully,


(P.K. Thakur)

**Renewal of Blood
Centre License No.
KD - 36**

File No. CLAA/B&BP/MAHA/30/2015-D
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Blood Centre Division)

FDA Bhawan, Kotla Road,
New Delhi-110002,
Dated:-

05 APR 2023

To

The Joint Commissioner (K. D.),
Food and Drug Administration, M.S.
Vardan (MIDC) Building, 1st & 9th Floor,
Road No. 16, Wagle Estate, Thane (West)-400604

Subject: Renewal of Blood Centre Licence no. KD-36 granted on 04.05.2006 for the period of 04.05.2021 to 03.05.2026 for the processing of Whole Human Blood IP & its components including apheresis issued in favor of M/s. Mahatama Gandhi Mission's Medical College & Hospital Blood Centre situated at Sector-18, Kamothe, Navi Mumbai-410209, Maharashtra-reg.

Ref. No. – Your office letter no. Renewal/BC/MGM/1130-2022/Z-1 dated 14.12.2022.

Sir,

With reference to the letter cited above on the subject matter, CLAA hereby approves the renewal of Blood Centre Licence no. KD-36 granted on 04.05.2006 for the period of 04.05.2021 to 03.05.2026 for the processing of Whole Human Blood IP & its components including apheresis issued in favor of M/s. Mahatama Gandhi Mission's Medical College & Hospital Blood Centre situated at Sector-18, Kamothe, Navi Mumbai-410209, Maharashtra.


Two copies of the renewal certificates duly approved by the CLAA are enclosed herewith for further necessary action by your Administration.

1. The Blood Centre may be re-inspected periodically at least once in a year from the date of licensing by a team comprising of Drugs Inspectors of CDSCO and State Licensing Authority and if required with an expert. The report may be forwarded to this Directorate for information.
2. The Blood Centre should comply with all the provisions prescribed under schedule F Part XII-B of the Drugs Rules.

It shall be ensured before issuance of renewal certificates that the educational qualification and experience of Dr. Iqbal Singh endorsed under license is as per the requirements of Drugs Rules 1945 and documents in support shall be submitted to this office.

Enclosure: Renewal certificate in Duplicate as above.

Yours faithfully,



(Dr. RAJEEV SINGH RAGHUVANSHI)
CENTRAL LICENCE APPROVING AUTHORITY

Copy forwarded for information to:

- The Deputy Drugs Controller (I), CDSCO, West Zone, 4th floor, Zonal FDA Bhawan, GMSD Compound, Bellasis Rd, Mumbai Central, Mumbai-400008.
- M/s. Mahatama Gandhi Mission's Medical College & Hospital Blood Centre situated at Sector-18, Kamothe, Navi Mumbai-410209, Maharashtra.



Form 26-G
(See Rule 122-F)

**CERTIFICATE OF RENEWAL OF LICENCE TO OPERATE A BLOOD CENTRE FOR
PROCESSING OF WHOLE HUMAN BLOOD AND/OR* FOR PREPARATION
FOR SALE OR DISTRIBUTION OF ITS COMPONENTS**

1. Certified that Licence (28C) No. KD-36 granted on 04.05.2006 to **M/s. Mahatma Gandhi Mission's Medical College & Hospital Blood Centre**, for the operation of blood centre for processing of Whole Human Blood and/ or for preparation of its components at the premises situated at **Sector-10, Kamothe, Navi Mumbai-410209, Taluka Panvel, Dist. Raigad, Maharashtra State** is hereby renewed with effect from 04.05.2021 to 03.05.2026.

2. Name (s) of Items :

1. Whole Human Blood I.P.

3. Fresh Frozen Plasma B.P.

5. Platelet Concentrate USP (RDP)

7. Single Donor Platelets (Apheresis)

2. Cryoprecipitate USP

4. Packed Red Cell Concentrate I.P.

6. Saline washed Red Cells USP

3. Name(s) of competent Technical Staff :

(a) Name(s) of Medical Officer :-

1. Dr. Iqbal Singh, M.B.B.S., M.D. Pathology

2. Dr. Shweta Dhote, M.B.B.S., M.D. Pathology

3. Dr. Moni Udani, M.B.B.S., M.D. IHB

4. Dr. Abhiniti Srivastava, M.B.B.S., IHB

5. Dr. Akanksha Jivrag, M.B.B.S., M.D. Pathology

Name(s) of Technician :-

1. Mrs. Manju A. Bhatti, B.Sc., P.G.D.M.L.T.

2. Mrs. Sharada A. Anchan, B.Sc., P.G.D.M.L.T.

3. Mr. Ravindra A. Attarde, B.Sc., P.G.D.M.L.T.

4. Mrs. Rohini Jadhav, B.Sc., P.G.D.M.L.T.

5. Mrs. Sandhya Powale, B.Sc., P.G.D.M.L.T.

(c) Name(s) of Registered Nurse :-

1. Mrs. Vaishali Urankar (GNM)

2. Mrs. Mariamma (GNM)

(d) Name(s) of Technical Supervisor : Mr. Abhay V. Firake, B.Sc., P.G.D.M.L.T.

Date :-

Signature

Name and Designation
Licensing Authority

(Dr. D. M. Bhamray)

Joint Commissioner (K. D.) &
Licensing Authority
Food and Drug Administration,
M.S., Thane


Central Licence Approving Authority

* delete, whichever is not applicable
DR. RAJEEV SINGH RAGHUVANSHI
Drug Controller General (India)
Central Drugs Standard Control Organisation
Directorate General of Health Services
Ministry of Health & Family Welfare
Government of India
F-10, Bhawan, Kotla Road,
New Delhi (India)

NIRF Overall

(Rank-band 151-200)



National Institutional Ranking Framework

Ministry of Education
Government of India



India Rankings 2023: University (Rank-band: 151-200)

Institution list in alphabetical order

[Back](#)

Name	City	State
Ahmedabad University	Ahmedabad	Gujarat
Amity University Rajasthan, Jaipur	Jaipur	Rajasthan
Anand Agricultural University	Anand	Gujarat
B. S. Abdur Rahman Crescent Institute of Science and Technology	Chennai	Tamil Nadu
Central Agricultural University	Imphal West	Manipur
Central University of Karnataka	Gulbarga	Karnataka
Central University of Rajasthan	Kishangarh	Rajasthan
Charotar University of Science & Technology	Changa	Gujarat
Chaudhary Sarwan Kumar Himachal Pradesh Krishi Vishwavidyalaya	Kangra	Himachal Pradesh
Dharmsinh Desai University	Nadiad	Gujarat
Dr Rajendra Prasad Central Agricultural University, Samastipur	Samastipur	Bihar
English & Foreign Languages University	Hyderabad	Telangana
Fakir Mohan University	Balasore	Odisha
Guru Angad Dev Veterinary & Animal Sciences University	Ludhiana	Punjab
JSS Science and Technology University	Mysuru	Karnataka
Kakatiya University	Hanumakonda	Telangana
Kannur University	Kannur	Kerala
Karnataka Veterinary, Animal & Fisheries Science University, Nandinagar	Bidar	Karnataka
Karpagam Academy of Higher Education	Coimbatore	Tamil Nadu
KLE Technological University	Dharwad	Karnataka
LNCT University	Bhopal	Madhya Pradesh
Maharashi Markandeshwar University, Solan	Solan	Himachal Pradesh
Mahatma Phule Krishi Vidyapeeth, Rahuri	Rahuri	Maharashtra
Maulana Azad National Urdu University	Hyderabad	Telangana
MGM Institute of Health Sciences, Navi Mumbai	Navi Mumbai	Maharashtra
Pandit Deendayal Energy University	Gandhinagar	Gujarat
Parul University	Vadodara	Gujarat
Pravara Institute of Medical Sciences, Ahmednagar	Ahmednagar	Maharashtra
Pt. Ravishankar Shukla University	Raipur	Chhattisgarh
Rabindranath Tagore University	Raisen	Madhya Pradesh
Rajasthan University of Health Sciences, Jaipur	Jaipur	Rajasthan
Rashtriya Sanskrit Sansthan, New Delhi	Delhi	Delhi
Sant Longowal Institute of Engineering & Technology	Longowal	Punjab
Shivaji University	Kolhapur	Maharashtra
Shri Mata Vaishno Devi University	Katra	Jammu and Kashmir
Sikkim University	Gangtok	Sikkim
Sri Chandrasekharendra Saraswathi Viswa Mahavidyalaya	Kancheepuram	Tamil Nadu
Sri Devraj Urs Academy of Higher Education and Research	Kolar	Karnataka
Sri Karan Narendra Agriculture University	JOBNER	Rajasthan
Sri Padmavathi Mahila Viswavidyalayam	Tirupathi	Andhra Pradesh
Sri Sathya Sai Institute of Higher Learning	Anantapur	Andhra Pradesh
Sri Venkateswara Institute of Medical Sciences	Tirupati	Andhra Pradesh
Sumandeep Vidyapeeth, Vadodara	Vadodara	Gujarat

**3 Star Certificate of
Institution's Innovation
Council (IIC)
Academic Year 2022-23**



Ministry of
Education
Government of India



MoE's
INNOVATION CELL
(GOVERNMENT OF INDIA)



INSTITUTION'S
INNOVATION
COUNCIL
(Ministry of Education Initiative)



CERTIFICATE

Institution's Innovation Council (IIC) established at

MGM Institute of Health Sciences, Navi Mumbai

had undertaken various activities prescribed by Innovation Cell, Ministry of Education, Govt. of India to promote Innovation and Start-up in campus during the IIC calendar year 2022-23.

Prop. TG Sitharam
Chairman
Aicte

Dr. Abhay Jere
Chief Innovation Officer
MOE, Innovation Cell

Mr. Dipan Sahu
Assistant Innovation Director
MOE, Innovation Cell

Certificate No : 2167

Issued On : 2023-11-16

SIRo Renewal



सूचना
का अधिकार

TELEGRAM : SCINDRECH
दूरभाष/TEL : 26962819, 26567373
(EPBAX) : 26565694, 26562133
: 26565687, 26562144
: 26562134, 26562122
फैक्स/FAX : 26960629, 26529745
Website : <http://www.dsir.gov.in>



सत्यमेव जयते

भारत सरकार

विज्ञान और प्रौद्योगिकी मंत्रालय
वैज्ञानिक और औद्योगिक अनुसंधान विभाग
टेक्नोलॉजी भवन, नया महरौली मार्ग,
नई दिल्ली - 110 016

GOVERNMENT OF INDIA

MINISTRY OF SCIENCE AND TECHNOLOGY
Department of Scientific and Industrial Research
Technology Bhavan, New Mehrauli Road,
New Delhi - 110 016



F.No. 14/791/2019-TU-V

Date: 23rd March 2022

The Vice Chancellor
MGM Institute of Health Sciences
(Deemed to be University),
Sector -1, Kamothe,
Navi Mumbai - 410209, Maharashtra

Subject: Renewal of Recognition of Scientific and Industrial Research Organisations (SIROs).

Dear Sir,

This has reference to your application for renewal of recognition of **MGM Institute of Health Sciences (Deemed to be University), Navi Mumbai, Maharashtra** as a Scientific and Industrial Research Organisation (SIRO) by the Department of Scientific and Industrial Research under the Scheme on Recognition of Scientific and Industrial Research Organisations (SIROs), 1988.

2. This is to inform you that it has been decided to accord renewal of recognition to **MGM Institute of Health Sciences (Deemed to be University), Navi Mumbai, Maharashtra from 01.04.2022 to 31.03.2025**. The recognition is subject to terms and conditions mentioned overleaf.

3. Receipt of this letter may kindly be acknowledged.

Yours faithfully,

(Dr. P.K. Dutta)
Scientist - 'F'

TERMS AND CONDITIONS FOR RECOGNITION OF SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONS (SIROs)

1. The organizations should acknowledge receipt of the recognition letter by stating that they will abide by the terms and conditions of recognition.
2. The recognition will entitle the SIRO to receive such administrative support from the DSIR, Ministry of Science & Technology as may be required on issue to promote or encourage scientific research activities.
3. SIROs recognized by DSIR are also deemed to be registered. A separate certificate of registration** is issued along with the recognition letter. The recognition would be valid for the period specified in the recognition letter and application for renewal of recognition shall be submitted in the prescribed proforma at least 3 months before the expiry of the valid recognition. Failure to submit application in time may lead to automatic lapsing of the recognition & registration.
***However, the certificate of registration is not issued to SIROs engaged in activities falling within the definition of 'hospital' as per notification No. 51/96-Cus. Dt. 23.07.1996 issued by the Department of Revenue.*
4. The recognition of DSIR does not amount to approval u/s 35(1)(ii)/(iii) of Income Tax Act, 1961.
5. The registration will entitle the SIROs to avail of custom duty exemption on purchase of equipment, instruments, spares thereof, consumables, etc. used for research and development subject to relevant Government policies in force from time to time. Custom duty exemption has to be separately dealt with the customs authorities. The SIROs should abide by the terms & conditions of the customs notifications issued/amended from time to time.
6. Separate books of accounts shall be maintained by the SIRO for research & development activities and the R&D expenditure, both capital and recurring should be reflected the Annual Report and Statement of Accounts of the Organization in separate schedules.
7. Disposal/sale of equipment and products/prototypes/intermediates, if any, emanating from the R&D/pilot plant, should be intimated to DSIR immediately. The realization, if any, from above or any services rendered etc. shall be shown in the R&D accounts of the organization as income of the SIRO in the audited accounts as well as annual report and should be used or reinvested for research activities only. In case of disposal/sale of R&D equipment, clearance from custom authorities will also be required in view of the applicable notifications under which the equipment was imported/purchased in India.
8. Accelerated depreciation allowance as per Rule 5(2) of Income Tax Rules 1962 will be available on investments on plant & machinery by any industrial unit which has made these investments for the purpose of commercialization of technology/know-how acquired from a SIRO recognition by DSIR.
9. Brief summary of the achievements of the organization shall be submitted to the DSIR every year. This should include details related to papers published, patents obtained and process developed, new products introduced, awards & prizes received, copy of Annual Report and Statement of Accounts of the organization etc. List of equipment, instruments, parts and consumables imported/purchased using the duty exemption should also be submitted to DSIR along with the Annual Report.
10. Any violation of the terms & conditions mentioned-above and / or provisions of taxation in force will make the organization liable to de-recognition.
11. The organization will also conform to such other conditions for recognition stipulated in the Guidelines or as may be specifically provided in the recognition letter.

NABH
MGM Medical College, Kamothe

National Accreditation Board for Hospitals & Healthcare Providers

(Constituent Board of Quality Council of India)

CERTIFICATE OF ACCREDITATION

MGM Medical College & Hospital

Sector 01, Plot 1 & 2 Kamothe
Mumbai Pune Expressway, Raigad
Navi Mumbai - 410209, Maharashtra

has been assessed and found to comply with NABH
Accreditation Standards for Hospitals, 5th Edition. This certificate
is valid for the Scope as specified in the annexure subject to
continued compliance with the accreditation requirements.

Date of first Certification: September 16, 2020

Date of Previous Cycle

September 16, 2020 to September 15, 2023

Valid from : October 19, 2023

Valid thru : September 15, 2027



Certificate No.
H-2020-0742

Dr. Atul Mohan Kochhar
Chief Executive Officer

National Accreditation Board for Hospitals & Healthcare Providers, 5th Floor, ITPI Building, 4A, Ring Road, IP Estate, New Delhi 110 002, India
Phone: +91-11-42600600, Fax: +91-11-2332 3415 • Email: helpdesk@nabh.co • Website: www.nabh.co



SI No. 015971



NABH and the NABH Accreditation Standards for Hospitals are ISQua Accredited

NABH
MGM Medical College, Aurangabad

National Accreditation Board for Hospitals & Healthcare Providers

(Constituent Board of Quality Council of India)

CERTIFICATE OF ACCREDITATION

**MGM Medical College Hospital
and Medical Center Research Institute (MCRI)**

Central Naka Road, N-6, CIDCO
Aurangabad- 431003, Maharashtra
Renewal

has been assessed and found to comply with NABH
Accreditation Standards for Hospitals, 5th Edition. This certificate
is valid for the Scope as specified in the annexure subject to
continued compliance with the accreditation requirements.

Date of first Certification: September 16, 2018

Date of Previous Cycle:
September 16, 2018 - September 15, 2021

Valid from : September 15, 2022

Valid thru : September 15, 2025



Certificate No.
H-2018-0573

Dr. Atul Mohan Kochhar
Chief Executive Officer

National Accreditation Board for Hospitals & Healthcare Providers, 5th Floor, ITPI Building, 4A, Ring Road, IP Estate, New Delhi 110 002, India
Phone: +91-11-42600600, Fax: +91-11-2332 3415 • Email: helpdesk@nabh.co • Website: www.nabh.co



SI No. 011864



NABH and the NABH Accreditation Standards for Hospitals are ISQua Accredited

NABH
MGM Medical College, Vashi



SI No. 004315

004315

National Accreditation Board for Hospitals & Healthcare Providers

(Constituent Board of Quality Council of India)

National Accreditation Board for Hospitals & Healthcare Providers
5th Floor, ITPI Building, 4A, Ring Road, IP Estate, New Delhi 110 002, India
Phone: +91-11-42600600, Fax: +91-11-2332 3415 • Email: helpdesk@nabh.co • Website: www.nabh.co

SCOPE OF ACCREDITATION

MGM New Bombay Hospital

Sector 3, Plot 35, Vashi
Navi Mumbai - 400703, Maharashtra

Certificate No. H-2015-0305

Date of First Certification: June 04, 2018



Valid from : September 02, 2021
Valid thru : June 03, 2025

Clinical Services

- Anaesthesiology including Neuro anaesthesia
- Critical Care
- Cardiac Anaesthesia
- Cardiology
- Cardiothoracic and Vascular Surgery
- Clinical Haematology including Hemato-oncology
- Dermatology and Venereology
- Endocrinology
- Emergency Medicine
- General Medicine
- General Surgery including bariatric surgery
- Infectious Diseases
- Medical Gastroenterology
- Medical Oncology
- Nephrology
- Neurology
- Neurosurgery including Spine Surgery
- Obstetrics and Gynaecology including high risk obstetrics
- Ophthalmology
- Orthopaedic Surgery including Sports Medicine

- Otorhinolaryngology
- Paediatric Cardiology (Interventional and Non Interventional)
- Paediatric Gastroenterology
- Paediatric Surgery
- Plastic and Reconstructive Surgery
- Paediatrics including Neonatology
- Psychiatry (OPD)
- Respiratory Medicine
- Radiology including Neuro- Radiology
- Surgical Gastroenterology
- Surgical Oncology
- Transplant (Renal and Cornea)
- Thoracic Surgery
- Urology

Diagnostic Services

- 2 D Echo
- Audiometry
- Bone Densitometry
- CT Scanning
- DSA lab
- EEG
- EMG/EP
- Gamma Camera
- Holter Monitoring

- MRI
- Mammography
- Spirometry
- Tread Mill Testing
- Ultrasound
- Urodynamic Studies
- X-Ray

Laboratory Services

- Clinical Bio-Chemistry
- Clinical Microbiology and Serology
- Clinical Pathology
- Cytopathology
- Haematology
- Histopathology
- Molecular Biology

Pharmacy

- Dispensary

Transfusions Services

- Blood Transfusions services

Professions Allied to Medicine

- Dietetics
- Physiotherapy
- Psychology
- Speech and Language Therapy

Support Services

- Ambulance

H-2015-0305

**NABH**

NABH and the NABH Accreditation Standards for Hospitals are ISQua Accredited

Dr. Atul Mohan Kochhar
Chief Executive Officer

NABL
MGM Medical College, Kamothe



National Accreditation Board for
Testing and Calibration Laboratories

CERTIFICATE OF ACCREDITATION

MGM MEDICAL COLLEGE & HOSPITALS, CENTRAL LABORATORY

has been assessed and accredited in accordance with the standard

ISO 15189:2012

**"Medical laboratories - Requirements for quality and
competence"**

for its facilities at

PLOT NO 1 & 2, NH4 JUNCTION, SION - PANVEL EXPRESS WAY, MUMBAI, MAHARASHTRA, INDIA

in the field of

Medical Testing

Certificate Number: MC-2166

Issue Date: 26/04/2022

Valid Until:

25/04/2024

This certificate remains valid for the Scope of Accreditation as specified in the annexure subject to continued satisfactory compliance to the above standard & the relevant requirements of NABL.
(To see the scope of accreditation of this laboratory, you may also visit NABL website www.nabl-india.org)

Name of Legal Identity : Mahatma Gandhi Mission

Signed for and on behalf of NABL



N. Venkateswaran
Chief Executive Officer

NABL
MGM Medical College, Aurangabad



**National Accreditation Board for
Testing and Calibration Laboratories**

CERTIFICATE OF ACCREDITATION

**MGM'S CENTRAL PATHOLOGY
LABORATORY, MAHATMA GANDHI MISSION HOSPITAL**

has been assessed and accredited in accordance with the standard

ISO 15189:2012

**"Medical laboratories - Requirements for quality and
competence"**

for its facilities at

N-6, CIDCO, AURANGABAD, MAHARASHTRA, INDIA

in the field of

Medical Testing

Certificate Number: MC-2839

Issue Date: 29/06/2023

Valid Until: 28/06/2025

**This certificate remains valid for the Scope of Accreditation as specified in the annexure subject to continued
satisfactory compliance to the above standard & the relevant requirements of NABL.**

(To see the scope of accreditation of this laboratory, you may also visit NABL website www.nabl-india.org)

Name of Legal Identity: MAHATMA GANDHI MISSION HOSPITAL

Signed for and on behalf of NABL



**N. Venkateswaran
Chief Executive Officer**

NABL
MGM Medical College, Vashi



National Accreditation Board for
Testing and Calibration Laboratories

CERTIFICATE OF ACCREDITATION

**MGM NEW BOMBAY HOSPITAL VASHI PATHOLOGY
LABORATORY**

has been assessed and accredited in accordance with the standard

ISO 15189:2012

**"Medical laboratories - Requirements for quality and
competence"**

for its facilities at

PLOT NO: 35, SECTOR 3, VASHI, NAVI MUMBAI, THANE, MAHARASHTRA, INDIA

in the field of

Medical Testing

Certificate Number: MC-2140

Issue Date: 19/05/2022

Valid Until:

18/05/2024

This certificate remains valid for the Scope of Accreditation as specified in the annexure subject to continued satisfactory compliance to the above standard & the relevant requirements of NABL.
(To see the scope of accreditation of this laboratory, you may also visit NABL website www.nabl-india.org)

Name of Legal Identity : Mahatma Gandhi Mission

Signed for and on behalf of NABL



N. Venkateswaran
Chief Executive Officer

Neighborhood Youth Parliament and Y20 Consultation



MINISTRY OF YOUTH AFFAIRS AND SPORTS
GOVT. OF INDIA
NEHRU YUVA KENDRA - ALIBAUG



MGM Medical College &
MGMSBS
MGMIHS, Navi Mumbai



Memento of Appreciation

Hon. Dr. G.S. Narshetty

DEAN, MGM MEDICAL COLLEGE, MGMIHS, NAVI MUMBAI

We thank you for your support and guidance towards
Neighborhood Youth Parliament and Y20 Consultation and
making it a success.

वसुधैव कुटुम्बकम्

ONE EARTH • ONE FAMILY • ONE FUTURE

Eat Right Campus Certificate



Inspiring Trust, Assuring Safe & Nutritious Food
Ministry of Health and Family Welfare, Government of India



FOOD SAFETY AND STANDARDS
AUTHORITY OF INDIA

MGM Medical College and hospital , Navi Mumbai, Panvel, Raigad

is certified as



as per guidelines established by
Food Safety and Standards Authority of India



Excellent

Shri Arun Singhal
Chief Executive Officer
FSSAI

Auditing Partner
FSATO INSPECTION SERVICES

Training Partner
Parikshan

Implementation Partner
FDA Maharashtra - Raigad

Valid up to: 17 February 2024

Center of Excellence for Laparoscopy surgery by
Storz, Karl Storz endoscope.

KARL STORZ Endoscopy India Private Ltd. • 28, Barakhamba Road • New Delhi-110 001

The Dean
MGM Medical College
Aurangabad

Date : 21.01.2021

Dear Sir,

M/s KARL STORZ SE & CO. KG., GERMANY is a pioneer and world leader in Laparoscopy equipment and instruments. We are also a leading brand in India and provide the latest high-class equipment for laparoscopic surgery. We are actively involved and are at the forefront in training and up-gradation of the skills of practicing surgeons and residents across the country.

The Department of Surgery, MGM Medical College and Hospital, Aurangabad is performing high-quality Advanced Laparoscopic and Endoscopic surgeries. We appreciate MGM's vision to pass on the benefits of ultra-modern treatment facilities that are provided to the poorest of poor at a negligible cost.

We also admire the efforts taken by Dr. Pravin Suryawanshi, Professor & Head, Department of Surgery to propagate the art and skills of Laparoscopic Surgery amongst his surgical colleagues and residents. His academic and research contribution to the development of Laparoscopy is praiseworthy.

In appreciation of the quality of services and academic contribution by MGM's Department of Surgery KARL STORZ India Pvt. Ltd. takes great honour in recognizing your Centre as a **"Centre of Excellence for Laparoscopy Surgery"**.

To further improve the quality of services and the teaching and learning experience for the junior surgeons, we are happy to install our World-class High-End product at your premises. We have installed OR1, OT lights and AIDA (Advance Image Data Archiving System) worth more than Rs.60,00,000/- and other equipment at a very subsidized cost at your esteemed institution.

We are sure with this latest upgradation of the ultra-modern operation theatre will benefit many junior surgeons to be trained further for better patient outcome.

Looking forward to this long association for the development of laparoscopy as a sub-specialty.

Thanking you,


Praveen Singla
Business Manager - MAS



American Heart Association



American
Heart
Association.

International Training Agreement

Company Information:

International Training Center ("ITC"):	Mahatma Gandhi Mission Medical College and Hospital
Address:	MGM Medical College and Hospital, Plot No. 01 Sector 01 Kamothe, Navi Mumbai, Maharashtra 410209, India
Form of Organization:	Not for Profit / University

This Agreement is between the American Heart Association, Inc. ("AHA"), a New York not-for-profit corporation, having its principal offices at 7272 Greenville Avenue, Dallas, Texas 75231-4596, and ITC.

IN CONSIDERATION of the mutual promises contained herein, the parties agree as follows:

1. Term: Beginning Date: January 24, 2020. Ending Date: January 24, 2023. This Agreement will be in effect for a period of Three (3) calendar years. It may be renewed for additional one (1) year periods by letter issued from AHA.

2. AHA ECC Courses to be Taught by ITC:

Basic Life Support	Advanced Cardiac Life Support
Provider Course(s)	Provider Course(s)
Instructor Course(s)	Instructor Course(s)

3. Geographic Territory: India

4. Insurance: \$28,024.69 US

ITC will obtain and maintain at its expense, commencing upon the beginning date of this Agreement and during its entire term, liability insurance from a qualified insurance carrier, as set out above. This policy will specify that it may not be modified or canceled by the insurer, except after thirty (30) days prior written notice by the insurer. Upon execution of this Agreement ITC will provide the AHA with a certificate of insurance showing the required coverage.

5. Copyrights: ITC acknowledges and agrees that the AHA owns all copyrights in the ECC Materials, and ITC may not copy, or permit others to copy, distribute, perform or make derivative works based upon the ECC Materials, Course Completion Cards, or eCards.

6. Marks: ITC acknowledges the AHA's trademark rights and ownership of the name "American Heart Association", the heart-and-torch trademark and slogans (e.g., "Life is Why") (hereinafter "AHA Marks"). ITC will not use or display the AHA Marks. ITC shall not apply for any trademark registrations with respect to any AHA Marks or any marks similar to the AHA Marks.

7. Entire Agreement: This Agreement, including the terms and conditions set out on Page Two, contains the entire agreement between the parties relating to the rights granted and the obligations assumed.

EXECUTED by the parties on the date(s) set out below.

American Heart Association, Inc.


Signature: 

Name: Keith Jansen

Title: SVP, International

Date: January 24, 2020

International Training Center

Signature: 

Name: GURUNATH S NARSHETTY

Title: DEAN

Date: 18-02-2020



Emergency Cardiovascular Care International Programs - 7272 Greenville Avenue, Dallas, Texas 75231-4596

Form Date: November 9, 2015

INCHARGE
MGM SKILLS LAB
DATE: 25/01/2020

DIRECTOR
MGM SKILLS LAB
DATE: 25/01/2020

Definitions:

(a) "Program Guidelines" means the current *Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care*, Program Administration Manual: Guidelines for Program Administration and Training (hereinafter "PAM"), and AHA Instructor's Manuals, as they may be amended and/or supplemented by the AHA from time to time.

(b) "Course Completion Cards" or "Cards" are defined as documents made available or provided by AHA, and which indicate a student's successful completion of a specified Course.

(c) "Course" or "Courses" are defined as those courses that follow the curricula of the AHA and teach emergency cardiovascular care according to the Program Guidelines.

(d) "ECC Materials" are defined as emergency cardiovascular care textbooks and materials published by the AHA.

(e) "eCards" means those electronic records that Training Centers may distribute to, or provide access to, students pursuant to Program Guidelines to indicate that the student participated in or successfully completed a Course.

(f) "Instructors" are individuals who have successfully completed AHA authorized Provider and Instructor training and who are authorized by ITC to teach Provider courses to other individuals.

(g) "Training Sites" are organizations engaged or authorized by ITC to teach Courses under the auspices of ITC.

9. ITC Role and Responsibilities:

(a) ITC will teach Courses only within the Geographic Territory, and agrees to do so in compliance with the Program Guidelines.

(b) ITC may contract with other entities (hereinafter "Training Sites") who agree to teach Courses under the direction and guidance of ITC. ITC assumes full responsibility for the actions and performance of the Training Sites, and will ensure that Training Sites teach in compliance with the Program Guidelines.

(c) Periodically, as requested by the AHA, ITC will provide the AHA with a current and accurate list of Training Sites, Instructors, the number of students taught, and such other information as may be requested by AHA but only to the extent allowed by local law and the terms of any applicable consent, if required.

(d) ITC will insure that each student has individual possession of an authorized Course-specific textbook before, during, and after training.

(e) ITC will be responsible for the issuance and security of Course Completion Cards and eCards as outlined in the Program Guidelines: (i) ITC will establish a system for ensuring that Cards are issued only to authorized Training Sites. (ii) ITC and its authorized Training Sites will only issue the appropriate course-specific Course Completion Card or eCard to each student who successfully completes the applicable Course.

(f) ITC will obtain any and all required licenses, permits or documentation and is solely responsible for compliance with all laws and regulations applicable to training activities conducted under this Agreement. ITC will obtain any required or appropriate consent from each student before sharing that student's name and Course completion information with the AHA through AHA's online systems (which systems may include data storage outside of ITC's Territory).

10. Relationship of Parties:

The parties acknowledge and agree that each is an independent entity and, as such, neither party may represent itself as an employee, agent, or representative of the other; nor may it incur any

obligations on behalf of the other party.

11. Termination:

(a) The Agreement may be terminated by either party, without cause, upon sixty (60) calendar days' prior written notice.

(b) Either party may terminate this Agreement if the other party breaches any term or condition of this Agreement and fails to cure the breach within thirty (30) calendar days after receipt of written notice by the non-defaulting party. The following will also constitute breach or default under this Agreement: (i) Failure to exist or operate as a legal entity or to maintain an office address; or (ii) Assignment for the benefit of creditors, becoming generally insolvent, being placed in receivership or the filing by or against a party of a petition for bankruptcy or for entity reorganization under any bankruptcy act or similar statute.

(c) The AHA may terminate this Agreement upon written notice if it determines, in its sole discretion, that any of the activities permitted or contemplated under this Agreement pose a significant legal or business risk to the AHA.

(d) Notwithstanding anything to the contrary in this Agreement, AHA may terminate this Agreement if ITC or any Training Site conducts Courses in any country on which the United States government or other governmental entity (except those that are contrary to United States' laws), that (i) imposes sanctions that would prevent the AHA from conducting Courses either directly or indirectly in the country or (ii) for which ITC, Training Site or AHA must obtain a license from the applicable government to conduct Courses. If the United States government should impose sanctions on any country named in the Geographic Territory, the AHA at its option may (i) immediately terminate this Agreement as to that country in which event ITC and its Training Sites will immediately cease conducting Courses in the country, or (ii) may immediately terminate this Agreement in its entirety upon written notice to ITC.

(e) ITC will not distribute any AHA Course Completion Cards or eCards or designate itself, in any manner or any place, as an authorized ECC training center of AHA after this Agreement has been terminated or expired. In addition to any remedies by law or in equity available to AHA, ITC will pay the AHA Two Hundred Dollars (200 US\$) as a penalty for each Course Completion Card issued after termination or expiration of this Agreement. Upon termination or expiration of this Agreement, AHA shall have no liability or obligations to ITC, and ITC shall retain no rights under this Agreement.

12. Warranties:

(a) ITC warrants and represents to the AHA that as of the effective date and at all times during the term of this Agreement: (i) ITC, its agents, affiliates, members, representatives, distributors, contractors, and Training Sites will be in compliance with this Agreement, the provisions of the U.S. Foreign Corrupt Practices Act and all applicable U.S., local, state and federal laws and regulations, and applicable laws or regulations of any jurisdictions whose laws may apply; (ii) ITC is not a tobacco company, or a tobacco company corporate subsidiary or parent, nor does it receive revenue from tobacco products. "Subsidiary" and "parent" are defined as an entity in which there exists a direct or indirect Five Per Cent (5%) or greater ownership interest by a tobacco company.

(b) EXCEPT AS EXPRESSLY SET OUT IN THIS AGREEMENT, THERE ARE NO WARRANTIES, EXPRESS OR IMPLIED, BY OPERATION OF LAW OR OTHERWISE.

13. Indemnification and Liability:

(a) ITC will indemnify, defend and hold harmless

the AHA and its directors, officers, employees, agents, distributors, members, volunteers, successors and assigns from and against all suits, proceedings, actions, demands, claims, losses, liability, damages or expenses (including reasonable attorneys' fees and legal costs) arising from (i) ITC's performance or breach of its obligations under this Agreement, (ii) ITC's operation activities and/or distribution of Course Completions Cards, (iii) any breach or alleged breach of ITC's representations or warranties, (iv) any act or omission of ITC in any country in the Geographic Territory, and (v) any act or omission of Training Sites, Instructors, ITC's affiliates, agents, partners or representatives.

(b) The AHA will not be liable for any indirect, special, consequential or incidental damages, including lost profits or any other kind of damages, even if it has been warned of the possibility of such loss or damage. In no event will the AHA's liability under this Agreement exceed \$1,000 (US\$).

14. Force Majeure: Neither party will be in default under this Agreement, if such results, whether directly or indirectly, from fire, explosion, strike, freight embargo, vis major, or of the public enemy, war, terrorism, civil disturbance, act of any government, de jure or de facto, or agency or official thereof, labor shortage, transportation contingencies, unusually severe weather, default of manufacturer or a supplier, quarantine restrictions, epidemic, or catastrophe.

15. Notices: Any notice required or permitted under this Agreement, will be given in writing and will be deemed to have been duly given upon actual receipt if delivered personally or by courier with receipt obtained therefrom to the parties at their respective addresses.

16. Miscellaneous Provisions:

(a) This Agreement may not be assigned by ITC without the AHA's prior written consent.

(b) No amendment of this Agreement will be binding or enforceable on either party hereto unless in writing signed by both parties.

(c) Should any part, term, or provision of this Agreement be declared to be invalid, void, or unenforceable by a court of competent jurisdiction, all remaining parts, terms, and provisions hereof will remain in full force and effect, and will in no way be invalidated, impaired or affected thereby.

(d) This Agreement will be governed by the laws of the State of New York without regard to its conflict of laws provisions. Any controversy or claim arising out of or relating to this Agreement will be settled by arbitration in Dallas, Texas in accordance with the International Arbitration Rules of the American Arbitration Association. The language of the arbitration will be English. The arbitrators will have no authority to award punitive damages, and may not, in any event, make any ruling, finding, or award that does not conform to the terms and conditions of this Agreement. Judgment upon any award rendered through arbitration may be entered in any court having jurisdiction. Injunctive relief may be sought in any court of competent jurisdiction.

(e) This agreement contains the entire agreement between the parties and supersedes all prior written and oral communications. This Agreement will be written in and governed by the English language.

(f) AHA reserves the right to appoint other ITCs within the Geographic Territory.

(g) The following paragraphs and their subparagraphs will survive termination of this Agreement: 13 (Indemnification and Liability), 16(d) and 16(e)

IN CHARGE
MGM SKILLS LAB
DATE: 28/01/2020



DIRECTOR
MGM SKILLS LAB
DATE: 28/01/2020

Institutional Animal Ethics Committee (IAEC)

Navi Mumbai

No: 25/355/2009-AWD
Government of India
Ministry of Fisheries, Animal Husbandry and Dairying
Department of Animal Husbandry and Dairying
O/o Committee for the purpose of Control and Supervision of Experiments on Animals
(CPCSEA)

Delhi Milk Scheme Complex,
Shadipur, Delhi – 110008
Date: 03.03.2022

To,

Dr. Prakash Khandelwal, Chairman, IAEC
Mahatma Gandhi Mission's Medical College
Sector - 18, Kamothe, Navi Mumbai - 410209, Maharashtra
Email: drkhandelwalpn@gmail.com
Mobile: 9822072226

Subject: Renewal of Registration and Reconstitution of Institutional Animals Ethics Committee (IAEC)- regarding

Sir,

The registration of Animal House Facility of your establishment with CPCSEA has been **renewed for a period of five years from the date of issue of this letter.**

2. The new registration number of Animal House Facility of your establishment is **303/PO/Re/S/2000/CPCSEA for Research for Education purpose on small animals.** Henceforth, the new registration number may kindly be quoted in all your future correspondence with this office.

3. The CPCSEA has accepted the following members recommended by the establishment.

Name of the IAEC Members	Designation in IAEC
1) Dr. Prakash Khandelwal	Biological Scientist, Chairperson
2) Dr. Ipseeta Ray	Scientist from different biological discipline, Member Secretary
3) Dr. Yashoda Kattimani	Scientist from different biological discipline
4) Dr. G S Narshetty	Scientist In charge of Animal House Facility
5) Dr. Krutika Khiratkar	Veterinarian

4. CPCSEA hereby nominates the following members to the Institutional Animals Ethics Committee (IAEC) of your establishment:

Details of Nominee(s)	Nominated as
1) Dr. K. Pani Prasad Principal Scientist, ICAR – Central Institute of Fisheries Education, Yari Raod, Panch Marg, Varsova, Mumbai – 400061, Maharashtra Contact No :9867241101 Email : kpaniprasad@cife.edu.in	Main Nominee
2) Dr. Arvind Ingle Scientific Officer 'F', Tata Memorial Centre, ACTREC, Navi Mumbai- 410210, MS Contact No :09969855176 Email : aingle@actrec.gov.in	Link Nominee

Contd..

3) Dr. Prabhakar S. Ukale Veterinarian, Animal House Facility, Institute of Chemical Technology, Nathalal Parekh Marg, Matunga East, Mumbai – 400019, Maharashtra Contact No :9029938325, 7021420723 Email : prabhukale@gmail.com	Scientist from outside the Institute
4) Shri Sharad Bhagat Technical Officer – A, ICMR National Institute for Research in Reproductive Health Department of Biochemistry & Virology, J M Street, Parel, Mumbai – 400012, Maharashtra Contact No :9869748756 Email :sharadbiotech@gmail.com	Socially Aware Nominee

(Please note that any change in IAEC members can be made only with prior approval of CPCSEA.)

5. The IAEC is valid for a period of five years and is coterminous with renewed period of registration. IAEC is required to be reconstituted at the time of renewal of registration as per CPCSEA guidelines.

6. You are requested to convene the meeting of the re-constituted IAEC within a period of 30 days and upload the same on the website of the CPCSEA.

7. It is stated that only above approved IAEC members shall sign, with date, on the attendance sheet of the IAEC meetings, and decisions will be taken only in meetings where quorum is complete. The quorum for holding IAEC meeting is six (6), and Main Nominee, Scientist from outside the Institute and Socially Aware Nominee must be present in such meetings. Link Nominee can attend in case main nominee conveys his unavailability in writing to the chairman IAEC. However, Link Nominee should be invited once in a year to update him/ her about the activities of IAEC. Any decision taken in the meetings of IAEC without quorum shall be considered invalid.

8. It is also to inform you that before commencing any research on large animals you are required to send research protocols with due recommendation of IAEC to CPCSEA for further approval (procedure for submission of Research Protocols is available on the website of CPCSEA).

Yours sincerely,

(Dr. S. K. Dutta)
Member Secretary (CPCSEA)

Copy for necessary action to: Nominees of CPCSEA.

The Main Nominee is requested to ensure that the IAEC meetings are held regularly as stipulated in the SOP of CPCSEA and submit the Annual Inspection Reports of the Animal House Facility regularly on the Website of CPCSEA.

The Main Nominee is requested to conduct the Inspection of Animal House Facility within a period of 30 days and submit the Inspection Report on the Website of CPCSEA

Institutional Animal Ethics Committee (IAEC)

Aurangabad

No: 25/30/2014-CPCSEA
Government of India
Ministry of Fisheries, Animal Husbandry and Dairying
Department of Animal Husbandry and Dairying
O/o Committee for the purpose of Control and Supervision of Experiments on Animals
(CPCSEA)

Krishi Bhawan, New Delhi-110001
Date: 02/Jun/2021

To,

Dr. Deepali Jaybhaye, Chairperson, IAEC,
MGM Medical College,
N-6, CIDCO, Aurangabad - 431003, Maharashtra.
Mobile: 8788461417
E-mail: deepalijaybhaye@rediffmail.com

Subject: Revision of Institutional Animals Ethics Committee (IAEC) – regarding

Madam,

Kindly refer to your application on the above subject. CPCSEA hereby accords approval to your request for revision of IAEC.


2. Accordingly, the revised IAEC is as under:

S.No.	Name of IAEC Members	Designation in IAEC
1	Dr. Sambhaji Shinde	Biological Scientist
2	Dr. Sangita Phatale	Scientist from different biological discipline, Member Secretary
3	Dr. Vishvesh Bansal	Scientist from different biological discipline
4	Dr. Deepali Jaybhaye	Scientist In charge of Animal House Facility, Chairperson
5	Dr. Upendra T. Mundhe	Veterinarian
6	Dr. Shrikant B. Satale	Main Nominee
7	Dr. Aman B. Upaganlawar	Link Nominee
8	Dr. Chandrashekhar Upasani	Scientist from outside the Institute
9	Dr. Jaykumar S. Satav	Socially Aware Nominee

3. It is stated that only above approved IAEC members shall sign, with date, on the attendance sheet of the IAEC meetings, and decisions will be taken only in meetings where quorum is complete. The quorum for holding IAEC meeting is six (6). and Main Nominee, Scientist from outside the Institute and Socially Aware Nominee must be present in such meetings. Link Nominee can attend in case main nominee conveys his unavailability in writing to the chairman IAEC. However, Link Nominee should be invited once in a year to update him/ her about the activities of IAEC. Any decision taken in the meetings of IAEC without quorum shall be considered invalid.

4. The above composition of IAEC is valid upto the renewed period of registration i.e. 27/08/2022.

Yours sincerely,


(Dr. S. K. Dutta)

Member Secretary (CPCSEA)

Copy for information to Nominees of CPCSEA:

1Dr. Shrikant B. Satale, Main Nominee

2Dr. Aman B. Upaganlawar, Link Nominee

3Dr. Chandrashekhar Upasani, Scientist from outside the Institute

4Dr. Jaykumar S. Satav, Socially Aware Nominee



भारत सरकार
मत्स्यपालन, पशुपालन और डेयरी मंत्रालय
पशुपालन और डेयरी विभाग
पशुओं पर परीक्षण के नियंत्रण एवं पर्यवेक्षण के प्रयोजनार्थ समिति (सीपीसीएसइए)

Government of India
Ministry of Fisheries, Animal Husbandry and Dairying
Department of Animal Husbandry and Dairying
Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA)



Date: 03/08/2022

Name of the establishment	MGM Medical College
Address of Animal House Facility	N-6, CIDCO, Aurangabad - 431003, Maharashtra
Purpose of Fee	Renewal
Tel No	8788461417
Email	deepalijaybhave@rediffmail.com
Purpose of Registration	
Total Fee Required	Rs.2500.0000
Fee Received through DD	Rs.0.0000
Fee Already Received through Online	Rs.0.0000
Fee Paid	Rs.2500.0000

Professor & H.O.D.
Department of Pharmacology
MGM's Medical College
Aurangabad.



भारत सरकार
पर्यावरण, वन एवं जलवायु परिवर्तन मंत्रालय
पशु कल्याण प्रभाग
पशुओं पर परीक्षण के नियंत्रण एवं पर्यवेक्षण के प्रयोजनार्थ समिति (सीपीसीएसईए)
Government of India
Ministry of Environment, Forest and Climate Change
Animal Welfare Division
Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA)



F. No. 25/127/2010-AWD
02/05/2018

To

Dr. Savita Shahani, Chairperson IAEC,
Mahatma Gandhi Mission's Medical College,
Sector - 18, Kamathe, Navi Mumbai - 410209, Maharashtra,
Mobile: 9819277578
E-mail: drshahanirediffmail@yahoo.co.in

Subject: Revision of Institutional Animals Ethics Committee (IAEC) – regarding

Madam,

Kindly refer to your application on the above subject. CPCSEA hereby accords approval to your request for revision of IAEC.

2. Accordingly, the revised IAEC is as under:

S.No.	Name of IAEC Members	Designation in IAEC
1.	Dr. Savita Shahani	Biological Scientist(Chairperson)
2.	Dr. Ipseeta Ray	Scientist from different biological discipline(Member Secretary)
3.	Dr. R S Inamdar	Scientist from different biological discipline
4.	Dr. G S Narshetty	Scientist Incharge of Animal House Facility
5.	Dr. Mohan Latkar	Veterinarian
6.	Dr. Uddhav Kalu Chaudhari	Main Nominee
7.	Dr. Vikas D. Dighe	Link Nominee
8.	Dr. Dhanjit Kumar Das	Scientist from outside the Institute
9.	Prof. Vishnu N. Thakare	Socially Aware Nominee

Contd.,

[Signature]


5वां तल, वायु ब्लॉक, इंदिरा पर्यावरण भवन, जोर बाग रोड नई दिल्ली-110003
दूरभाष : 011-24695231, टेलीफैक्स : 011-24695424 ईमेल : cpcsea-me@gov.in, वेबसाइट : <http://cpcsea.nic.in>

5th Floor, Vayu Block, Indira Parvatan Bhawan, Jor Bagh Road, New Delhi-110003
Phone: 011-24695231, Telefax : 011-24695424, Email: cpcsea-me@gov.in, Website: <http://cpcsea.nic.in>

3. It is stated that only above approved IAEC members shall sign, with date, on the attendance sheet of the IAEC meetings, and decisions will be taken only in meetings where quorum is complete. The quorum for holding IAEC meeting is six(6), and CPCSEA Nominees must be present in such meetings. Link Nominee can attend in case main nominee conveys his unavailability in writing to the chairman IAEC. Socially aware member's presence is compulsory in cases referred to CPCSEA and at least in one meeting in a Calendar year. Any decision taken in the meetings of IAEC without quorum shall be considered invalid.

4. The above composition of IAEC is valid upto the renewed period of registration i.e. 18.01.2022.

Yours faithfully,



(S. P. Singh)

Under Secretary (CPCSEA)

Copy for information to Nominees of CPCSEA:

1. Dr. Uddhav Kalu Chaudhari- Main Nominee
2. Dr. Vikas D. Dighe- Link Nominee
3. Dr. Dhanjit Kumar Das- Scientist from outside the Institute
4. Prof. Vishnu N. Thakare- Socially Aware Nominee

**Ethics Committee Registration
Division
MGM Institute of Health Sciences,
Navi Mumbai**

2nd Floor, IRCS Building,
New Delhi - 110001
Dated : 27-Jan-2022

Subject: Provisional registration of the Ethics Committee relating to Biomedical and Health Research with the National Ethics Committee Registry for Biomedical and Health Research (NECRBHR), Department of Health Research (DHR).

In exercise of the powers conferred by sub-rule (3) of rule 17 of the New Drugs and Clinical Trials Rules, 2019, the designated authority in the Department of Health Research, Ministry of Health & Family Welfare, hereby provisionally registers and permits the following Ethics Committee to perform the duties of ethics committee as specified in Chapter-IV of the New Drugs and Clinical Trials Rules, 2019.

Name : MGM Medical College Institutional Ethics Committee, Navi Mumbai,

Address : MGM Medical College and Hospital, Navi Mumbai, Sector-1, Kamothe,
Navi Mumbai, 410209., Navi Mumbai, Raigad, Maharashtra - 410209

Contact No: 022-27433404, 27437991, 27437992

Fax : 022-27431094

2. The Ethics Committee shall observe all the conditions as stipulated in Chapter-IV of the aforesaid Rules, i.e., New Drugs and Clinical Trials Rules, 2019 and the National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, specified by the Indian Council of Medical Research (ICMR).

3. The designated authority shall scrutinize the documents and information furnished with the application by the Ethics Committee for the issue of final registration certificate.

4. The above provisional registration shall be valid for a maximum period of two years from the date of its issue or till grant of final registration or rejection of provisional registration, whichever is earlier.

(Anu Nagar)
Joint Secretary
Department of Health Research
Designated Authority

Fwd: Recognition of your Institute as Adverse Drug Reactions Monitoring Centre (AMC) under PvPI

2 messages

Deepanjana Dass <ddass1985@gmail.com>
To: "iqac@mgmuhs.com" <iqac@mgmuhs.com>

Tue, Feb 14, 2023 at 5:49 PM

Dear Madam,

Kindly find the attached trailing email from NCC Ghaziabad, as an approval of MGM MC, Navi Mumbai as an AMC.

Regards,
Dr. Deepanjana

----- Forwarded message -----

From: **NCC PvPI** <pvpi.ipc@gov.in>

Date: Tue, Dec 7, 2021, 18:31

Subject: Re: Recognition of your Institute as Adverse Drug Reactions Monitoring Centre (AMC) under PvPI

To:

Cc: JAIPRAKASH JAIPRAKASH <jaiprakash.ipc@gov.in>, SHASHI BHUSHAN <bshashi.ipc@gov.in>

Sir/Madam,

Greeting from NCC-PvPI !!!

This is with reference to your letter of intent to participate in a nationwide programme to monitor the safety of drugs. It is a matter of great pleasure to bring in your kind notice that the Indian Pharmacopoeia Commission (IPC), National Coordination Centre (NCC) - **Pharmacovigilance Programme of India (PvPI)**, Ghaziabad has approved your institution as an Adverse Drug Reactions Monitoring Centre under PvPI.

The detailed roles, responsibilities of Coordinator and Deputy Coordinator of AMC are attached herewith.

Kindly go through and send your acceptance within 5 days.

Please accept our heartiest congratulations.

On behalf of

(Dr. Jai Prakash)
Sr.PSO, Officer-in-Charge, PvPI

Thanks & Regards

Anusha
HR Associate

--
Follow Us on

[Click here for PV Guidance Document](#)



2 attachments



twitter_icon.png
2K



Roles & Responsibilities of AMC Coordinator.doc
72K

Deepanjana Dass <ddass1985@gmail.com>
To: iqac@mgmuhs.com

Tue, Feb 14, 2023 at 5:54 PM

Dear Madam,

Kindly find the attached trailing email as a copy of approval of MGM MC, Navi Mumbai as an ADR Monitoring Centre.
[Quoted text hidden]

2 attachments



fb_icon.png
3K



Roles & Responsibilities of AMC Coordinator.doc
72K



File No. EC/19/000510
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,
New Delhi - 110002, India
Dated: 20-Mar-2020

To

The Chairman
Ethics Committee for Research on Human Subjects
MGM Institute of Health Sciences
Sector -1 Kamothe Navi Mumbai Raigad Maharashtra -
410209 India

Subject: Ethics Committee Re-Registration No. ECR/457/Inst/MH/2013/RR-20 issued under New Drugs and Clinical Trials Rules, 2019.

Sir/Madam,

Please refer to your application no. EC/RENEW/INST/2019/6200 dated 30-Sep-2019 submitted to this Directorate for the Re-Registration of Ethics Committee.

Please find enclosed registration of the Ethics Committee in Form CT-02 vide Registration No. ECR/457/Inst/MH/2013/RR-20. The said registration is subject to the conditions as mentioned below:-

Yours faithfully

(Dr. V.G. Somani)
Drugs Controller General (I) &
Central Licensing Authority

Conditions of Registration

1. The registration is valid from 20-Mar-2020 to 19-Mar-2025, unless suspended or cancelled by the Central Licencing Authority.
2. This certificate is issued to you on the basis of declaration/submission made by you.
3. Composition of the said Ethics Committee is as per the Annexure.
4. No clinical trial or bioavailability or bioequivalence protocol and related documents shall be reviewed by an Ethics Committee in meeting unless at least five of its members as detailed below are present in the meeting, namely:-
 - (i) medical scientist (preferably a pharmacologist);
 - (ii) clinician;
 - (iii) legal expert;
 - (iv) social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person;
 - (v) lay person.
5. The Ethics Committee shall have a minimum of seven and maximum of fifteen members from medical,

non-medical, scientific and non-scientific areas with at least,

- (i) one lay person;
- (ii) one woman member;
- (iii) one legal expert;
- (iv) one independent member from any other related field such as social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian.

6. One member of the Ethics Committee who is not affiliated with the institute or organization shall be the Chairperson, and shall be appointed by such institute or organization and one member who is affiliated with the institute or organization shall be appointed as Member Secretary of the Ethics Committee by such Institute or organization.

7. The Ethics Committee shall consist of at least fifty percent of its members who are not affiliated with the institute or organization in which such committee is constituted.

8. The committee shall include at least one member whose primary area of interest or specialisation is non-scientific and at least one member who is independent of the institution.

9. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.

10. Members should be conversant with the provisions of New Drug and Clinical Trials Rules, 2019, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.

11. The members representing medical scientists and clinicians shall possess at least post graduate qualification in their respective area of specialization, adequate experience in the respective fields and requisite knowledge and clarity about their role and responsibility as committee members.

12. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.

13. The Ethics Committee may associate such experts who are not its members, in its deliberations but such experts shall not have voting rights, if any

14. No member of an Ethics Committee, having a conflict of interest, shall be involved in the oversight of the Clinical trial or bioavailability or bioequivalence study protocol being reviewed by it and all members shall sign a declaration to the effect that there is no conflict of interest.

15. While considering an application which involves a conflict of interest of any member of the Ethics Committee, such member may voluntarily withdraw from the Ethics Committee review meeting, by expressing the same in writing, to the Chairperson. The details in respect of the conflict of interest of the member shall be duly recorded in the minutes of the meetings of the Ethics Committee.

16. Any change in the membership or the constitution of the registered Ethics Committee shall be intimated in writing to the Central Licencing Authority within thirty working days.

17. The Ethics Committee shall review and accord approval to a Clinical trial, Bioavailability and Bioequivalence study protocol and other related documents, as the case may be, in the format specified in clause (B) of Table 1 of the Third Schedule of New Drugs and Clinical Trials Rules, 2019 and oversee the conduct of clinical trial to safeguard the rights, safety and wellbeing of trial subjects in accordance with these rules, Good Clinical Practices Guidelines and other applicable regulations.

18. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7: provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be: provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site.

19. Where a Bioavailability or Bioequivalence study centre does not have its own Ethics Committee, bioavailability or bioequivalence study at that site may be initiated after obtaining approval of the protocol from the Ethics Committee registered under rule 8: Provided that the approving Ethics Committee shall

such case be responsible for the study at the centre: Provided further that both the approving Ethics Committee and the centre, shall be located within the same city or within a radius of 50 kms of the bioavailability or bioequivalence study centre.

20. Ethics committee shall indicate the reasons that weighed with it while rejecting or asking for a change or notification in the protocol in writing and a copy of such reasons shall also be made available to the Central Licencing Authority.

21. Ethics committee shall make, at appropriate intervals, an on-going review of the trials for which they have reviewed the protocol. Such a review may be based on the periodic study progress reports furnished by the investigators or monitoring and internal audit reports furnished by the sponsor or by visiting the study sites.

22. Where any serious adverse event occurs to a trial subject or to study subject during clinical trial or bioavailability or bioequivalence study, the Ethics Committee shall analyse the relevant documents pertaining to such event and forward its report to the Central Licencing Authority and comply with the provisions of Chapter VI, New Drugs and Clinical Trials Rules, 2019.

23. The Ethics committee shall undertake proper causality assessment of SAE's with the help of subject experts wherever required, for deciding relatedness and quantum of compensation, as per condition no (22) mentioned above.

24. Where at any stage of a clinical trial, it comes to a conclusion that the trial is likely to compromise the right, safety or wellbeing of the trial subject, the Ethics committee may order discontinuation or suspension of the clinical trial and the same shall be intimated to the head of the institution conducting clinical trial and the Central Licencing Authority.

25. Ethics committee shall comply with the requirements or conditions in addition to the requirements specified under the Drugs & Cosmetics Act, 1940 and New Drugs and Clinical Trials Rules, 2019, as may be specified by the Central Licencing Authority with the approval of the Central Government, to safeguard the rights of clinical trial subject or bioavailability or bioequivalence study subject.

26. Ethics Committee shall review and approve the suitability of the investigator and trial site for the proposed trial.

27. The Ethics Committee shall maintain data, record, registers and other documents related to the functioning and review of clinical trial or bioavailability study or bioequivalence study, as the case may be, for a period of five years after completion of such clinical trial.

28. Funding mechanism for the Ethics Committee to support their operations should be designed and approved to ensure that the committee and their members have no financial incentive to approve or reject particular study.

29. SOP's for funding of the Ethics committee in order to support their operations must be maintained. The records of income & expenditure of Ethics Committee shall be maintained for review and inspection.

30. The Chairman of Ethics Committee shall enter into MOU with head of institution, that necessary support and facilities and independence will be provided to Ethics Committee and their records will be maintained.

31. The Ethics Committee shall allow any officer authorized by the Central Licencing Authority to enter, with or without prior notice, to inspect the premises, any record, or any documents related to clinical trial, furnish information to any query raised by such authorized person, in relation to the conduct of clinical trial and to verify compliance with the requirements of these rules, Good Clinical Practices Guidelines and other applicable regulations for safeguarding the rights, safety and well-being of trial subjects.

32. Where Central Licencing Authority is of the opinion that Ethics Committee fails to comply with any provision of the Drugs and Cosmetics Act, 1940 and New Drugs & Clinical Trials Rules, 2019, it may issue show cause notice to such Ethics Committee specifying therein such non-compliances and the period within which reply shall be furnished by such Ethics Committee. After consideration of the facts and reply given by the Ethics Committee, the Central Licencing Authority may take one or more actions specified under provision of Rule 14, Chapter III of New Drugs and Clinical Trials Rules, 2019.




File No. EC/19/000510
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,
New Delhi - 110002, India
Dated: 20-Mar-2020

Composition of the Ethics Committee:-

Sr. No.	Name of Member	Qualification	Role/Designation in Ethics Committee
1	Dr. Shirish Joshi	MBBS (MD-Pharmacology)	Basic Medical Scientist
2	Dr. Prakash Prabhakar Rao Doke	MBBS (PSM)	Clinician
3	Dr. G.S Narshetty	MBBS (MS Surgery)	Clinician
4	Dr. Alaka Deshpande	MBBS (MD Medicine)	Chair Person
5	Dr. Savita Ramesh Shahani	MBBS (MD Pharmacology)	Member Secretary
6	Dr. KARUNA RAMRAJE MALVIYA	Others (Master of Law)	Legal Expert
7	Mr. Eknath A Patil	B. COM (CA)	Lay Person
8	Mr. Jagdish Chandra Sharma	BSc (MPhil)	Social Scientist
9	Dr. Chander Prakash Puri	BSc (PhD)	Scientific Member
10	Dr. Smita Mahale	Ph.D	Scientific Member
11	Dr. Abhijit De	M.Phil, Ph.D (Cytogenetics)	Scientific Member
12	Dr. Ipseeta Ray	Ph.D	Scientific Member
13	Dr. Atmaram Bandivdekar	Ph.D	Scientific Member
14	Dr. Raman P. Yadav	Ph.D	Scientific Member

(Dr. V.G. Somani)
Drugs Controller General (I) &
Central Licensing Authority



**Government of India
Ministry of Health & Family Welfare
Department of Health Research**

2nd Floor, IRCS Building,
New Delhi - 110001
Dated : 27-Jan-2022

Provisional Certificate

Subject: Provisional registration of the Ethics Committee relating to Biomedical and Health Research with the National Ethics Committee Registry for Biomedical and Health Research (NECRBHR), Department of Health Research (DHR).

In exercise of the powers conferred by sub-rule (3) of rule 17 of the New Drugs and Clinical Trials Rules, 2019, the designated authority in the Department of Health Research, Ministry of Health & Family Welfare, hereby provisionally registers and permits the following Ethics Committee to perform the duties of ethics committee as specified in Chapter-IV of the New Drugs and Clinical Trials Rules, 2019.

Name : MGM Medical College Institutional Ethics Committee, Navi Mumbai,
Address : MGM Medical College and Hospital, Navi Mumbai, Sector-1, Kamothe, Navi Mumbai, 410209., Navi Mumbai, Raigad, Maharashtra - 410209
Contact No: 022-27433404, 27437991, 27437992
Fax : 022-27431094

2. The Ethics Committee shall observe all the conditions as stipulated in Chapter-IV of the aforesaid Rules, i.e., New Drugs and Clinical Trials Rules, 2019 and the National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, specified by the Indian Council of Medical Research (ICMR).

3. The designated authority shall scrutinize the documents and information furnished with the application by the Ethics Committee for the issue of final registration certificate.

4. The above provisional registration shall be valid for a maximum period of two years from the date of its issue or till grant of final registration or rejection of provisional registration, whichever is earlier.

(Anu Nagar)
Joint Secretary
Department of Health Research
Designated Authority

**Ethics Committee Registration
Division
MGM Medical College And Hospital,
Aurangabad**

ECR/1083/MGM-ECRHS/Inst/MH/2014/Re-Registration-2020

Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,
New Delhi – 110 002, India
Dated:

To

01 JUN 2021

The Chairman
MGM Ethics Committee for Research on Human Subjects
MGM Medical College and Hospital, N-6, CIDCO
Aurangabad- 431003, Maharashtra, India

Subject: Ethics Committee Re-registration No. ECR/581/Inst/MH/2014/RR-20, amendment to the composition of the Ethics Committee-regarding.

Sir/Madam,

Please refer to your application submitted to this Directorate for change in composition of the Re-registered Ethics Committee

Based on the documents submitted by you, the composition of your Ethics Committee bearing Registration number ECR/581/Inst/MH/2014/RR-20 dated 07.10.2020 valid until 10.09.2025 is hereby amended as follows, with all conditions of the Registration Certificate initially granted to you, remaining the same including the condition that "the Ethics Committee shall review and accord approval to Clinical Trial and BA/BE Study protocol of new drugs and also conduct periodic review of the studies as per the New Drugs and Clinical Trial Rules, 2019".

Sr. No.	Name of member	Qualification	Role/Designation in Ethics Committee
1.	Dr. Sachin S. Bhagwat	M.Sc, PhD	Chairperson
2.	Dr. Jyoti Anil Bobde	MBBS, MD	Member Secretary
3.	Dr. S. H. Talib	MBBS, MD (General Medicine)	Clinician
4.	Dr. Laxmi N. Rachakonda	MBBS, MD (Obst & Gyne)	Clinician
5.	Dr. S M Mahajan	MBBS, MD (Epidemiology)	Clinician
6.	Dr. A. G. Shroff	MBBS, MD (Anatomy)	Medical Scientist
7.	Dr. Suparna Milind Bindu	MBBS, MD (Pathology)	Medical Scientist
8.	Mr. Mangesh V Shinde	B.Ed, M.Ed	Lay Person
9.	Mr. Abhaysinh K Bhosle	LLB, LLM	Legal Expert
10.	Mr. Sanjay Sewalikar	B.Com, MSW	Social Scientist
11.	Ms. Kanwaljeet Kaur	BSc. MSc.-Nursing	Scientific Member
12.	Dr. Sarah Babu Venkatesan	BPT, PhD	Scientific Member

Yours faithfully

(Dr. V. G. Somani)
Central Licensing Authority



Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,
New Delhi - 110002, India
Dated: 07-Oct-2020

To

The Chairman
MGM ETHICS COMMITTEE FOR RESEARCH ON
HUMAN SUBJECT
MGM Medical College And Hospital
N-6 , CIDCO Aurangabad Aurangabad
Maharashtra - 431003 India

Subject: Ethics Committee Re-Registration No. ECR/581/Inst/MH/2014/RR-20 issued under New Drugs and Clinical Trials Rules, 2019.

Sir/Madam,

Please refer to your application no. EC/RENEW/INST/2020/9615 dated 09-Sep-2020 submitted to this Directorate for the Re-Registration of Ethics Committee.

Please find enclosed registration of the Ethics Committee in Form CT-02 vide Registration No. ECR/581/Inst/MH/2014/RR-20. The said registration is subject to the conditions as mentioned below:-

Yours faithfully

(Dr. V.G. Somani)
Drugs Controller General (I) &
Central Licensing Authority

Conditions of Registration

1. The registration is valid from 11-Sep-2020 to 10-Sep-2025, unless suspended or cancelled by the Central Licencing Authority.
2. This certificate is issued to you on the basis of declaration/submission made by you.
3. Composition of the said Ethics Committee is as per the Annexure.
4. No clinical trial or bioavailability or bioequivalence protocol and related documents shall be reviewed by an Ethics Committee in meeting unless at least five of its members as detailed below are present in the meeting, namely:-
 - (i) medical scientist (preferably a pharmacologist);
 - (ii) clinician;
 - (iii) legal expert;
 - (iv) social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person;
 - (v) lay person.

5. The Ethics Committee shall have a minimum of seven and maximum of fifteen members from medical, non-medical, scientific and non-scientific areas with at least,
- (i) one lay person;
 - (ii) one woman member;
 - (iii) one legal expert;
 - (iv) one independent member from any other related field such as social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian.
6. One member of the Ethics Committee who is not affiliated with the institute or organization shall be the Chairperson, and shall be appointed by such institute or organization and one member who is affiliated with the institute or organization shall be appointed as Member Secretary of the Ethics Committee by such Institute or organization.
7. The Ethics Committee shall consist of at least fifty percent of its members who are not affiliated with the institute or organization in which such committee is constituted.
8. The committee shall include at least one member whose primary area of interest or specialisation is non-scientific and at least one member who is independent of the institution.
9. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.
10. Members should be conversant with the provisions of New Drug and Clinical Trials Rules, 2019, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.
11. The members representing medical scientists and clinicians shall possess at least post graduate qualification in their respective area of specialization, adequate experience in the respective fields and requisite knowledge and clarity about their role and responsibility as committee members.
12. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.
13. The Ethics Committee may associate such experts who are not its members, in its deliberations but such experts shall not have voting rights, if any
14. No member of an Ethics Committee, having a conflict of interest, shall be involved in the oversight of the Clinical trial or bioavailability or bioequivalence study protocol being reviewed by it and all members shall sign a declaration to the effect that there is no conflict of interest.
15. While considering an application which involves a conflict of interest of any member of the Ethics Committee, such member may voluntarily withdraw from the Ethics Committee review meeting, by expressing the same in writing, to the Chairperson. The details in respect of the conflict of interest of the member shall be duly recorded in the minutes of the meetings of the Ethics Committee.
16. Any change in the membership or the constitution of the registered Ethics Committee shall be intimated in writing to the Central Licencing Authority within thirty working days.
17. The Ethics Committee shall review and accord approval to a Clinical trial, Bioavailability and Bioequivalence study protocol and other related documents, as the case may be, in the format specified in clause (B) of Table 1 of the Third Schedule of New Drugs and Clinical Trials Rules, 2019 and oversee the conduct of clinical trial to safeguard the rights, safety and wellbeing of trial subjects in accordance with these rules, Good Clinical Practices Guidelines and other applicable regulations.
18. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7: provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be: provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site.
19. Where a Bioavailability or Bioequivalence study centre does not have its own Ethics Committee, bioavailability or bioequivalence study at that site may be initiated after obtaining approval of the

from the Ethics Committee registered under rule 8: Provided that the approving Ethics Committee shall in such case be responsible for the study at the centre: Provided further that both the approving Ethics Committee and the centre, shall be located within the same city or within a radius of 50 kms of the bioavailability or bioequivalence study centre.

20. Ethics committee shall indicate the reasons that weighed with it while rejecting or asking for a change or notification in the protocol in writing and a copy of such reasons shall also be made available to the Central Licencing Authority.

21. Ethics committee shall make, at appropriate intervals, an on-going review of the trials for which they have reviewed the protocol. Such a review may be based on the periodic study progress reports furnished by the investigators or monitoring and internal audit reports furnished by the sponsor or by visiting the study sites.

22. Where any serious adverse event occurs to a trial subject or to study subject during clinical trial or bioavailability or bioequivalence study, the Ethics Committee shall analyse the relevant documents pertaining to such event and forward its report to the Central Licencing Authority and comply with the provisions of Chapter VI, New Drugs and Clinical Trials Rules, 2019.

23. The Ethics committee shall undertake proper causality assessment of SAE's with the help of subject experts wherever required, for deciding relatedness and quantum of compensation, as per condition no (22) mentioned above.

24. Where at any stage of a clinical trial, it comes to a conclusion that the trial is likely to compromise the right, safety or wellbeing of the trial subject, the Ethics committee may order discontinuation or suspension of the clinical trial and the same shall be intimated to the head of the institution conducting clinical trial and the Central Licencing Authority.

25. Ethics committee shall comply with the requirements or conditions in addition to the requirements specified under the Drugs & Cosmetics Act, 1940 and New Drugs and Clinical Trials Rules, 2019, as may be specified by the Central Licencing Authority with the approval of the Central Government, to safeguard the rights of clinical trial subject or bioavailability or bioequivalence study subject.

26. Ethics Committee shall review and approve the suitability of the investigator and trial site for the proposed trial.

27. The Ethics Committee shall maintain data, record, registers and other documents related to the functioning and review of clinical trial or bioavailability study or bioequivalence study, as the case may be, for a period of five years after completion of such clinical trial.

28. Funding mechanism for the Ethics Committee to support their operations should be designed and approved to ensure that the committee and their members have no financial incentive to approve or reject particular study.

29. SOP's for funding of the Ethics committee in order to support their operations must be maintained. The records of income & expenditure of Ethics Committee shall be maintained for review and inspection.

30. The Chairman of Ethics Committee shall enter into MOU with head of institution, that necessary support and facilities and independence will be provided to Ethics Committee and their records will be maintained.

31. The Ethics Committee shall allow any officer authorized by the Central Licencing Authority to enter, with or without prior notice, to inspect the premises, any record, or any documents related to clinical trial, furnish information to any query raised by such authorized person, in relation to the conduct of clinical trial and to verify compliance with the requirements of these rules, Good Clinical Practices Guidelines and other applicable regulations for safeguarding the rights, safety and well-being of trial subjects.

32. Where Central Licencing Authority is of the opinion that Ethics Committee fails to comply with any provision of the Drugs and Cosmetics Act, 1940 and New Drugs & Clinical Trials Rules, 2019, it may issue show cause notice to such Ethics Committee specifying therein such non-compliances and the period within which reply shall be furnished by such Ethics Committee. After consideration of the facts and reply given by the Ethics Committee, the Central Licencing Authority may take one or more actions specified under provision of Rule 14, Chapter III of New Drugs and Clinical Trials Rules, 2019.



File No. EC/20/000329
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,
New Delhi - 110002, India
Dated: 07-Oct-2020

Composition of the Ethics Committee:-

Sr. No.	Name of Member	Qualification	Role/Designation in Ethics Committee
1	Mr. Abhaysinh K Bhosle	LLB (Master of Laws (LL.M.))	Legal Expert
2	Dr. Shafat Husain Talib	MBBS (MD - General Medicine)	Clinician
3	Dr. Lakshmi Nagabhushanam Rachakonda	MBBS (MD - Obstetrics & Gynaecology)	Clinician
4	Dr. Gautam Ajit Shroff	MBBS (MD/MS - Anatomy)	Basic Medical Scientist
5	Dr. Manvendra Sawalaram Kachole	BSc (M.Sc)	Chair Person
6	Dr. Jyoti Anil Bobde	MBBS (MD)	Member Secretary
7	Dr. Suparna Milind Bindu	MBBS (MD Pathology)	Basic Medical Scientist
8	Dr. Sarath Babu Venkatesan	BPT (Ph.D)	Scientific Member
9	Dr. S M Mahajan	MBBS (MD-Epidemiologist)	Clinician
10	Ms. Kanwaljeet Kaur	BSc (MSc-Nursing)	Scientific Member
11	Mr. Sanjay Sewalikar	B. COM (MSW-Master in Social Work)	Social Scientist
12	Mr. Mangesh V Shinde	B.Ed (M.Ed)	Lay Person

(Dr. V.G. Somani)
Drugs Controller General (I) &
Central Licensing Authority

**Zonal Transplantation
Coordination Center,
Aurangabad**

No. 4401



नोंदणी प्रमाणपत्र


याद्वारे प्रमाणपत्र देण्यात येते की, खाली वर्णन केलेली सार्वजनिक विश्वस्तव्यवस्था ही आज, मुंबई सार्वजनिक विश्वस्तव्यवस्था अधिनियम, १९५० (सन १९५० चा मुंबई अधिनियम २९) या अन्वये Aurangabad Region, Aurangabad येथील सार्वजनिक विश्वस्तव्यवस्था नोंदणी कार्यालयात योग्य रितीने नोंदण्यात आलेली आहे.

सार्वजनिक विश्वस्तव्यवस्थेचे नाव : Zonal Transplantation
Coordination Center, Aurangabad.

सार्वजनिक विश्वस्तव्यवस्थांच्या नोंदणी पुस्तकातील क्रमांक : E - 1298 (A. bad)
Dr. Sudhir Gajanan Kulkarni यांस प्रमाणपत्र दिले.

आज दिनांक 12 04.2016 २०१६

रोजी माझ्या सहीनिशी दिले.



सही [Signature] 12/4/16
आयुक्त सहायक धर्मार्थ आरक्षण अधिकारी
पदनाम [Signature] यांचे, औरंगाबाद

महाराष्ट्र शासन

सार्वजनिक आरोग्य विभाग

शासन निर्णय क्रमांक: माअप्र-२०१८/प्र.क्र.२२०/आरोग्य-६

गो.ते.रुग्णालय आवार संकुल इमारत,

१०वा मजला, नवीन मंत्रालय, मुंबई-०१

दिनांक: ०७ डिसेंबर, २०१८

वाचा :-

- १) वैद्यकीय शिक्षण व औषधी द्रव्ये विभाग, अधिसूचना क्र. SWP-०४१४/C.R.०८/Acts, दिनांक ३०.०६.२०१८
- २) समुचित प्राधिकारी (माअप्र) तथा संचालक, आरोग्य सेवा संचालनालय, मुंबई यांचे पत्र क्र. संआसे/माअप्र/लोकलऑथोकमिट/नामनिर्देशितप्रतिनिधी/७६३/२०१८, दिनांक ३०.११.२०१८

प्रस्तावना :-

वैद्यकीय शिक्षण व औषधी द्रव्ये विभागाच्या संदर्भाधिन क्र. १ येथील दिनांक ३०.०६.२०१८ च्या अधिसूचनेन्वये १६ रुग्णालयांमध्ये मानवी अवयव व उत्ती प्रत्यारोपण अधिनियम, १९९४ अंतर्गत Hospital Based Authorization समिती गठीत करण्यात आलेली आहे. सदर समितीमध्ये अ.क्र.६ येथे अपर मुख्य सचिव/प्रधान सचिव/सचिव, सार्वजनिक आरोग्य विभाग किंवा त्यांचे Nominee यांचा समितीचे सदस्य म्हणून समावेश करण्यात आला आहे. संदर्भाधिन क्र. २ येथील संचालक, आरोग्य सेवा यांचेकडून प्राप्त प्रस्तावास अनुसरून मानवी अवयव प्राधिकार समितीच्या बैठकांना उपस्थित राहण्याकरीता अपर मुख्य सचिव/प्रधान सचिव/सचिव, सार्वजनिक आरोग्य विभाग व संचालक, आरोग्य सेवा यांचे प्रतिनिधी नामनिर्देशित करण्याची बाब शासनाच्या विचाराधीन होती.

शासन निर्णय:-

मानवी अवयव व उत्ती प्रत्यारोपण अधिनियमांतर्गत गठीत Hospital Based Authorization समितीच्या बैठकांना उपस्थित राहण्याकरीता अपर मुख्य सचिव/प्रधान सचिव/सचिव, सार्वजनिक आरोग्य विभाग व संचालक, आरोग्य सेवा यांचे प्रतिनिधी म्हणून खालीलप्रमाणे नामनिर्देशित करण्यात येत आहे.

अ.क्र.	रुग्णालयाचे नाव	अपर मुख्य सचिव/ प्रधान सचिव/ सचिव (सा.आ.वि.) यांचे प्रतिनिधी	संचालक, आरोग्य सेवा यांचे प्रतिनिधी
१	बॉम्बे हॉस्पिटल, मुंबई	वैद्यकीय अधीक्षक, सामान्य रुग्णालय, मालवणी, मालाड, मुंबई	सहायक संचालक, ठाणे
२	जसलोक हॉस्पिटल, मुंबई		
३	पी.डी.हिंदुजा हॉस्पिटल, माहिम, मुंबई		
४	व्होकार्ड हॉस्पिटल, मुंबई सेंट्रल, मुंबई		
५	कोकीलाबेन धिरुभाई अंबानी		

	हॉस्पिटल, अंधेरी, मुंबई		
६	ग्लोबल हॉस्पिटल, परेल, मुंबई	वैद्यकीय	अतिरिक्त जिल्हा शल्य
७	फोर्टीस हॉस्पिटल, मुलुंड, मुंबई	अधिक्षक, मनोरुग्णालय, ठाणे	चिकीत्सक, जिल्हा
८	ज्युपिटर हॉस्पिटल, ठाणे		रुग्णालय, ठाणे
९	अपोलो हॉस्पिटल, बेलापूर, नवी मुंबई	वैद्यकीय अधिक्षक, उपजिल्हा रुग्णालय, पनवेल	जिल्हा शल्य चिकीत्सक, जिल्हा रुग्णालय, ठाणे
१०	आदित्य बिर्ला हॉस्पिटल, चिंचवड, पुणे	सहायक संचालक, पुणे	जिल्हा शल्य चिकीत्सक, जिल्हा रुग्णालय, औंध, पुणे
११	दिनानाथ मंगेशकर हॉस्पिटल, एरंडवणे, पुणे		
१२	सहयाद्री हॉस्पिटल, एरंडवणे, पुणे		
१३	जहांगीर हॉस्पिटल, ससून रोड, पुणे	वैद्यकीय अधिक्षक, मनोरुग्णालय, पुणे	अतिरिक्त जिल्हा शल्य चिकीत्सक, जिल्हा रुग्णालय, पुणे
१४	रुबी हॉल क्लिनिक, ससून रोड, पुणे		
१५	कमलनयन बजाज हॉस्पिटल, औरंगाबाद	सहायक संचालक, औरंगाबाद	जिल्हा शल्य चिकीत्सक, जिल्हा रुग्णालय, औरंगाबाद
१६	एमजीएम हॉस्पिटल, औरंगाबाद		

२. सदर शासन निर्णय महाराष्ट्र शासनाच्या www.maharashtra.gov.in या संकेतस्थळावर उपलब्ध करण्यात आला असून त्याचा सांकेतांक 201812071439599217 असा आहे. हा आदेश डिजिटल स्वाक्षरीने साक्षांकित करून काढण्यात येत आहे.

महाराष्ट्राचे राज्यपाल यांच्या आदेशानुसार व नावाने,

(सु.नि.गाडगे)

कार्यासन अधिकारी, महाराष्ट्र शासन

प्रत,

- १) मा. राज्यपाल यांचे सचिव, राजभवन, मुंबई
- २) मा. मुख्यमंत्री यांचे प्रधान सचिव, मंत्रालय, मुंबई
- ३) मा.मंत्री (सार्वजनिक आरोग्य व कुटुंब कल्याण) यांचे खाजगी सचिव, मंत्रालय, मुंबई
- ४) मा. राज्यमंत्री (सार्वजनिक आरोग्य व कुटुंब कल्याण) यांचे खाजगी सचिव, मंत्रालय, मुंबई
- ५) मुख्य सचिव, महाराष्ट्र राज्य, मंत्रालय, मुंबई

- ६) प्रधान सचिव, सार्वजनिक आरोग्य विभाग, नवीन मंत्रालय, मुंबई
- ७) प्रधान सचिव, विधि व न्याय विभाग, मंत्रालय, मुंबई
- ८) सचिव, वैद्यकीय शिक्षण व औषधी द्रव्ये विभाग, नवीन मंत्रालय, मुंबई
- ९) आयुक्त, आरोग्य सेवा तथा अभियान संचालक, राष्ट्रीय आरोग्य अभियान, मुंबई
- १०) विधि सल्लागार-नि-सहसचिव, विधि व न्याय विभाग, मंत्रालय, मुंबई
- ११) संचालक, आरोग्य सेवा, आरोग्य सेवा संचालनालय, मुंबई
- १२) संचालक, वैद्यकीय शिक्षण व संशोधन संचालनालय, मुंबई
- १३) जिल्हाधिकारी (सर्व)
- १४) सहसंचालक, आरोग्य सेवा (रुग्णालये/राज्यस्तर), आरोग्य सेवा संचालनालय, मुंबई
- १५) सहसंचालक, आरोग्य सेवा (सर्व)
- १६) उपसंचालक, आरोग्य सेवा परिमंडळे (सर्व)
- १७) सहायक संचालक (माअप्र), आरोग्य सेवा संचालनालय, मुंबई.
- १८) जिल्हा शल्यचिकित्सक (सर्व)
- १९) निवड नस्ती (आरोग्य -६)



महाराष्ट्र शासन राजपत्र

असाधारण भाग चार-अ

वर्ष ४, अंक ८०]

शनिवार, जून ३०, २०१८/आषाढ ९, शके १९४०

[पृष्ठ ७, किंमत : रुपये १५.००

असाधारण क्रमांक १३३

प्राधिकृत प्रकाशन

महाराष्ट्र शासनाने केंद्रीय अधिनियमान्वये तयार केलेले
(भाग एक, एक-अ आणि एक-ल यांमध्ये प्रसिद्ध केलेले नियम व आदेश यांव्यतिरिक्त) नियम व आदेश.

MEDICAL EDUCATION AND DRUGS DEPARTMENT

New Mantralaya, 9th floor, Gokuldas Tejpal Hospital Complex,
Lokmanya Tilak Road, Mumbai 400 001, dated the 30th June 2018.

NOTIFICATION

TRANSPLANTATION OF HUMAN ORGANS AND TISSUES ACT, 1994.

No. SWP-0414/C.R.08/Acts.—In exercise of the powers conferred by clause (b) of sub-section (4) of section 9 of Transplantation of Human Organs and Tissues Act, 1994 (42 of 1994) read with rules 11 and 12 of the Transplantation of Human Organs and Tissues Rules, 2014, and of all other powers enabling it in that behalf and in supersession of all earlier notifications, orders or instruments issued in this behalf, the Government of Maharashtra, hereby, constitutes, the Hospital Based Authorization Committees, for the hospital in which more than 25 transplantations have been made as specified in the Schedule appended hereto and also appoints the Chairperson and Members thereof as specified in the Schedule, for the purposes of the said Act and rules made thereunder, as follows, namely :—

Schedule

(1) Hospital Based Authorization Committee at **Bombay Hospital, Marine Lines, Mumbai** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Rajkumar Patil
2	Member under clause (b) of Rule 12	Dr. Kapil Salagia
3	Member under clause (b) of Rule 12	Dr. Suresh Jain

(१)

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
4	Member under clause (c) of Rule 12	Dr. Smt. Sunita Kshirsagar.
5	Member under clause (c) of Rule 12	Dr. Vijay Punjabi
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(2) Hospital based Authorization Committee at **Fortis Hospital, Mulund, Mumbai** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. S. Narayani
2	Members under clause (b) of Rule 12	Dr. Pravin Shah
3	Members under clause (b) of Rule 12	Dr. Sandeep Gore
4	Member under clause (c) of Rule 12	Dr. Smt. Jesal Sheth
5	Member under clause (c) of Rule 12	Dr. Ramesh Punjani
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(3) Hospital based Authorization Committee at **Global Hospital, Parel, Mumbai** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Jigna Shortriya
2	Member under clause (b) of Rule 12	Dr. Rajiv Nikte
3	Member under clause (b) of Rule 12	Dr. Nirupa Borges
4	Member under clause (c) of Rule 12	Dr. Smt. Kajal Ahuja
5	Member under clause (c) of Rule 12	Dr. Pragji Vaja
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(4) Hospital based Authorization Committee at **Jaslok Hospital, Pedar Road, Mumbai** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Lalita Delima
2	Member under clause (b) of Rule 12	Dr. Minal Shah
3	Member under clause (b) of Rule 12	Dr. Ravindra Bendre
4	Member under clause (c) of Rule 12	Dr. Smt. Usha Shah
5	Member under clause (c) of Rule 12	Dr. Anil Pachnekar
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(5) Hospital based Authorization Committee at **Kokilaben Ambani Hospital, Andheri (West), Mumbai** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Ram Narayn
2	Member under clause (b) of Rule 12	Dr. Jotsna Oak
3	Member under clause (b) of Rule 12	Dr. Manohar Kamat
4	Member under clause (c) of Rule 12	Dr. Smt. Alka Rao
5	Member under clause (c) of Rule 12	Dr. Suraj Suchak
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(6) Hospital based Authorization Committee at **P. D. Hinduja Hospital, Mahim (West), Mumbai** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Sugandhi Iyer
2	Member under clause (b) of Rule 12	Dr. S. V. Prabhu
3	Member under clause (b) of Rule 12	Dr. C. V. Vanjani
4	Member under clause (c) of Rule 12	Dr. Mrs. Prarthana Utture
5	Member under clause (c) of Rule 12	Dr. Sudhir Patil
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(7) Hospital based Authorization Committee at **Wockhardt Hospital, Mumbai Central, Mumbai** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Parag Rindani
2	Member under clause (b) of Rule 12	Dr. Bchram Pardiwalla
3	Member under clause (b) of Rule 12	Dr. Dipti Patel
4	Member under clause (c) of Rule 12	Dr. Smt. Sujatunnisa Attar.
5	Member under clause (c) of Rule 12	Dr. Salim Sachani
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(8) Hospital based Authorization Committee at **Jupiter Hospital, Thane** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Ravindra Karnjekar
2	Member under clause (b) of Rule 12	Dr. Pankaj Joshi
3	Member under clause (b) of Rule 12	Dr. Nikhil Kamat
4	Member under clause (c) of Rule 12	Dr.Smt. Manjushri Vivek Birla.
5	Member under clause (c) of Rule 12	Dr. Mahesh Bedekar
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(9) Hospital based Authorization Committee at **Apollo Hospital, Navi Mumbai** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Narendra Trivedi
2	Member under clause (b) of Rule 12	Dr. Sobati Shyam
3	Member under clause (b) of Rule 12	Dr. Vishal Malhotra
4	Member under clause (c) of Rule 12	Dr. Smt. Alka Patnaik
5	Member under clause (c) of Rule 12	Dr. Gangadhar Maheshwari.

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(10) Hospital based Authorization Committee at **Aditya Birla Hospital, Pune** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Ashutosh Shrivastava
2	Member under clause (b) of Rule 12	Dr. Rahul Kallianpur
3	Member under clause (b) of Rule 12	Dr. Sandeep Bhavsar
4	Member under clause (c) of Rule 12	Dr. Smt. Pratibha Kane
5	Member under clause (c) of Rule 12	Dr. Raju Varyani
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(11) Hospital based Authorization Committee at **Deenanath Mangeshkar Hospital, Pune** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Utkrant Kurlekar
2	Member under clause (b) of Rule 12	Dr. Asmita Bhawe
3	Member under clause (b) of Rule 12	Dr. Jayant Agate
4	Member under clause (c) of Rule 12	Dr. Smt. Maya Tulpule
5	Member under clause (c) of Rule 12	Dr. Jayant Navarange
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(12) Hospital based Authorization Committee at **Sahyadri Super Specialty Hospital, Pune** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Deepa Divekar
2	Member under clause (b) of Rule 12	Dr. Jayshree Apte
3	Member under clause (b) of Rule 12	Dr. Dhananjay Chandkkar.
4	Member under clause (c) of Rule 12	Dr. Smt. Aarti Nimkar
5	Member under clause (c) of Rule 12	Dr. B. L. Deshmukh
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(13) Hospital based Authorization Committee at **Ruby Hall Clinic, Pune** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Sanjay Pathare
2	Member under clause (b) of Rule 12	Dr. N. C. Ydul
3	Member under clause (b) of Rule 12	Dr.C.P.Bajpai
4	Member under clause (c) of Rule 12	Dr. Smt. Padma Iyer
5	Member under clause (c) of Rule 12	Dr. Rajkumar Shah
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(14) Hospital based Authorization Committee at **Jahangir Hospital, Pune** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. N. G. Kamat
2	Member under clause (b) of Rule 12	Dr. Uma Divate
3	Member under clause (b) of Rule 12	Dr. Milind Botre
4	Member under clause (c) of Rule 12	Dr. Smt. Meenakshi Deshpande.
5	Member under clause (c) of Rule 12	Dr. Arun Haibe
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(15) Hospital based Authorization Committee at **Kamalnayan Bajaj Hospital, Aurangabad** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Alok Shrivastav
2	Member under clause (b) of Rule 12	Dr. S. P. Ekbote
3	Member under clause (b) of Rule 12	Dr. R. B. Sharma
4	Member under clause (c) of Rule 12	Dr. Smt. Ujwala Dahipale.
5	Member under clause (c) of Rule 12	Dr. Santosh Ranjalkar
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee.	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee.	Member.

(16) Hospital based Authorization Committee at **M. G. M. Hospital, Aurangabad** consisting of following Members :—

Sr. No. (1)	Rule (2)	Chairperson / Members (3)
1	Chairperson under clause (a) of Rule 12	Dr. Aparna Kakkad
2	Member under clause (b) of Rule 12	Dr. S. H. Talib
3	Member under clause (b) of Rule 12	Dr. S. A. Sami
4	Member under clause (c) of Rule 12	Dr. Smt. Rashmi Borikar.
5	Member under clause (c) of Rule 12	Dr. Yashwant Gade
6	Member under clause (d) of Rule 12 Additional Chief Secretary/ Principal Secretary/ Secretary Public Health Department or his nominee	Member
7	Member under clause (d) of Rule 12 Director of Health Service or his nominee	Member.

Note.—Terms and conditions of Chairperson and Members of Hospital based Authorization Committees :—

(1) Each member of Authorization Committee shall have equal power.

(2) No official members of Authorization Committee shall be entitled to Travelling Allowance and Daily Allowance as admissible to Group A members of State Government.

(3) The Quorum of the Authorization Committee shall be minimum four and the quorum should not be complete without the participation of the Chairperson, the presence of Secretary (Health) or nominee and Director of Health Services or his nominee.

By order and in the name of the Governor of Maharashtra,

SURENDRA P. CHANKAR,
Deputy Secretary to Government.

**List of IMA Members Hospital Based Authorization Committee with
their Mobile Numbers**

Sr. No.	Name of Hospital	Name of IMA Members with Mobile Numbers	
1.	Bombay Hospital, Mumbai	1.Dr.Sunita Kshirsagar	9820118181
		2. Dr.Vijay Panjabi	9821061205
2.	Global Hospital, Parel Mumbai	1. Dr.Smt. Kajal Ahuja	9833110302
		2. Dr. Pragji Vaja	9820482375
3.	Jaslok Hospital, Mumbai	1. Dr. Smt Usha Shah	9322004145
		2. Dr. Anil Pachnekar	9869001873
4.	P.D.Hinduja Hospital, Mahim	1. Dr. Smt. Prarthana Utture	9833556069
		2. Dr. Sudhir Patil	982030353
5.	Wockhardt Hospital, Bombay Central	1. Dr. Smt.Sujatunnisa Attar	7506033993
		2. Dr. Salim Sachani	9892631484
6.	Kokilaben Ambani Hospital, Andheri	1. Dr. Smt. Alka rao	9820338360
		2. Dr. Suraj Suchak	9920080151
7.	Fortis Hospital, Mulund	1. Dr. Smt.Sejal Sheth	9930951440
		2. Dr. Ramesh Punjani	9819327833
8.	Appolo Hospital Washi	1. Dr. Smt.Alka Patnaik	9323170532
		2. Dr. Gangadhar Maheshwari	9820011036
9.	Jupiter Thane	1. Dr.Smt.Manjushri Vivek Birla	9930140355
		2. Dr.Mahesh Bedekar	9821913638
10.	Aditya Birala Hospital, Pune	1. Dr.Smt.Pratibha Kane	9822090771
		2. Dr.Raju Vayani	9822646025
11.	Deenanath Mangeshkar Hosp.	1. Dr.Smt.Maya Tulpule	9823709210
		2. Dr.jayant Navrange	9561081674
12.	Sahaydri Super specility Hosp,Pune	1. Dr.Aarti Nimkar	9822304882
		2. Dr.B.L.Deshmukh	9960172759
13.	Jahangi Hospital, Pune	1. Dr.Meenakshi Deshpande	9922464365
		2. Dr.Arun Halbe	9423586343
14.	Ruby Hall clinic	1. Dr.Padma Iyer	9373305154
		2. Dr.Rajkumar Shah	9422500666
15.	Kamalnayan Bajaj Hosp,Aurangabad	1. Dr.Smt.Ujwala Dahiphale	
		2. Dr.Santosh Ranjalkar	
16.	M.G.M.Hosp, Aurangabad	1. Dr.Smt.Rashmi Borikar	
		2. Dr.Yashwant Gade	

Adverse Drug Reactions Monitoring Centre (AMC) Navi Mumbai

Fwd: Recognition of your Institute as Adverse Drug Reactions Monitoring Centre (AMC) under PvPI

2 messages

Deepanjana Dass <ddass1985@gmail.com>

Tue, Feb 14, 2023 at 5:49 PM

To: "iqac@mgmuhs.com" <iqac@mgmuhs.com>

Dear Madam,

Kindly find the attached trailing email from NCC Ghaziabad, as an approval of MGM MC, Navi Mumbai as an AMC.

Regards,
Dr. Deepanjana

----- Forwarded message -----

From: **NCC PvPI** <pvpi.ipc@gov.in>

Date: Tue, Dec 7, 2021, 18:31

Subject: Re: Recognition of your Institute as Adverse Drug Reactions Monitoring Centre (AMC) under PvPI

To:

Cc: JAIPRAKASH JAIPRAKASH <jaiprakash.ipc@gov.in>, SHASHI BHUSHAN <bshashi.ipc@gov.in>

Sir/Madam,

Greeting from NCC-PvPI !!!

This is with reference to your letter of intent to participate in a nationwide programme to monitor the safety of drugs. It is a matter of great pleasure to bring in your kind notice that the Indian Pharmacopoeia Commission (IPC), National Coordination Centre (NCC) - **Pharmacovigilance Programme of India (PvPI)**, Ghaziabad has approved your institution as an Adverse Drug Reactions Monitoring Centre under PvPI.

The detailed roles, responsibilities of Coordinator and Deputy Coordinator of AMC are attached herewith.

Kindly go through and send your acceptance within 5 days.

Please accept our heartiest congratulations.

On behalf of

(Dr. Jai Prakash)
Sr.PSO, Officer-in-Charge, PvPI

Thanks & Regards

Anusha
HR Associate

--
Follow Us on

[Click here for PV Guidance Document](#)



2 attachments



twitter_icon.png
2K



Roles & Responsibilities of AMC Coordinator.doc
72K

Deepanjana Dass <ddass1985@gmail.com>
To: iqac@mgmuhs.com

Tue, Feb 14, 2023 at 5:54 PM

Dear Madam,

Kindly find the attached trailing email as a copy of approval of MGM MC, Navi Mumbai as an ADR Monitoring Centre.
[Quoted text hidden]

2 attachments



fb_icon.png
3K



Roles & Responsibilities of AMC Coordinator.doc
72K

**Adverse Drug Reactions Monitoring Centre
(AMC)**

Aurangabad



INDIAN PHARMACOPOEIA COMMISSION

National Coordination Centre- Pharmacovigilance Programme of India (PvPI)

MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA

SECTOR-23, RAJ NAGAR, GHAZIABAD, U.P. 201 002.

Tel No: 0120- 2783392, 2783400, 2783401 Fax: 0120-2783311

e-mail: pvpi@ipcindia.net, ipclab@vsnl.net, Web: www.ipc.gov.in

File no.: IPC/NCC-PvPI/AMCs/2017-18/102

Date: 06/06/2017

To,

Dr. Abhijeet Bhagat,
Assistant Professor,
Department of Pharmacology,
Mahatma Gandhi Mission (MGM),
N-6, Cidco,
Aurangabad,
Maharashtra-431003

Sub: Recognition of your Institute as Adverse Drug Reactions Monitoring Centre (AMC) under PvPI.

Sir/Madam,

This is with reference to your letter of intent to participate in nationwide programme to monitor the safety of drugs, it is a matter of great pleasure to bring in your kind notice that the Indian Pharmacopoeia Commission (IPC), National Coordination Centre (NCC) - **Pharmacovigilance Programme of India (PvPI)**, Ghaziabad has agreed in principle to recognise your institution as an Adverse Drug Reactions Monitoring Centre under PvPI.

The detailed roles and responsibilities and resource materials will be sent to you after your acceptance.

Please accept our heartiest congratulations.

With regards

Yours faithfully

(Dr. G. N. Singh)

Secretary-cum-Scientific Director

Copy to:

- The Dean, Mahatma Gandhi Mission (MGM), Aurangabad, Maharashtra
- The Administrative Officer, Indian Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh
- The Finance & Accounts Officer, Indian Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh

"Let us join hands with PvPI to ensure patients safety"

ADR Reporting Helpline (Toll Free): 1800-180-3024